**Jean A. Frazier, MD**

Division of Child and Adolescent Psychiatry

University of Massachusetts Medical School

University of Massachusetts Memorial Health Care

55 Lake Ave., North

Worcester, MA 01655

774.455.4120 Phone

774.455.4111 Fax

[jean.frazier@umassmed.edu](mailto:jean.frazier@umassmed.edu)

**Education**

Research Fellowship in Child Psychiatry 1993 - 1995

Child Psychiatry Branch, National Institute of Mental Health, Bethesda, MD

Child and Adolescent Psychiatry Fellowship 1991 - 1993

Emma Pendleton Bradley Hospital, Brown Medical School, East Providence, RI

Adult Psychiatry Residency 1988 - 1990

Tufts-New England Medical Center, Boston, MA

Internship 1987 - 1988

Tufts-New England Medical Center, Boston, MA

M.D., Dartmouth Medical School, Hanover, N.H. 1987

B.A., (Music), Wellesley College, Wellesley, MA 1982

**Appointments: Academic**

Affiliated Faculty 2011 - pres.

Graduate School of Biomedical Sciences: *Neuroscience*

University of Massachusetts Medical School, Worcester, MA

Affiliated Faculty 2010 - pres.

Graduate School of Biomedical Sciences: *Clinical & Population Health Research*

University of Massachusetts Medical School, Worcester, MA

*Robert M. and Shirley S. Siff Endowed Chair in Autism* 2008 - pres.

Departments of Psychiatry and Pediatrics

University of Massachusetts Medical School, Worcester, MA

Professor 2008 - pres.

Departments of Psychiatry and Pediatrics,

University of Massachusetts Medical School, Worcester, MA

Associate Professor 2006 - 2008

Department of Psychiatry,

Harvard Medical School, Boston, MA

Visiting Scientist 1999 - 2000

Clinical Research Center

Massachusetts Institute of Technology, Cambridge, MA

Assistant Professor 1998 - 2006

Department of Psychiatry

Harvard Medical School, Boston, MA

Instructor 1995 - 1998

Department of Psychiatry

Harvard Medical School, Boston, MA

Research and Teaching Fellow 1991 - 1993

Department of Psychiatry

Brown University Medical School Providence, RI

Teaching Fellow 1987 - 1991

Department of Psychiatry

Tufts Medical School, Boston, MA

**Administrative Appointments: Clinical**

Founder *and* Medical Director 2013 - pres.

Center for Autism and Neurodevelopmental Disorders (CANDO Interdisciplinary Clinic) Department of Psychiatry

University of Massachusetts Medical School

UMass Memorial Health Care, Worcester, MA

Director 2008 - pres.

Division of Child and Adolescent Psychiatry

Department of Psychiatry

University of Massachusetts Medical School

UMass Memorial Health Care, Worcester, MA

Medical Director 2004 - 2008

Center for Child and Adolescent Development

Cambridge Health Alliance, Cambridge, MA

Director 2004 - 2008

Child and Adolescent Psychopharmacology

Cambridge Health Alliance, Cambridge, MA

Director 1999 - 2004

Child and Adolescent Psychiatry Outpatient Program

McLean Hospital, Belmont, MA

Chief Resident in Psychiatry 1990 - 1991

Adult Psychiatry Residency Program

Tufts-New England Medical Center, Boston, MA

**Administrative Appointments: Research**

UMMS/UMMHC Site Director 2016 - pres

Fragile X Clinical & Research Consortium

Executive Director

Eunice Kennedy Shriver Center at UMMS 2015 - pres.

University of Massachusetts Medical School

Worcester, MA

Co-Director 2013 - 2015

Intellectual and Developmental Disability Research Center (IDDRC)

The Eunice Kennedy Shriver Center

University of Massachusetts Medical School

Worcester, MA

Co-Director 2012 - 2015

Core A, Intellectual and Developmental Disability Research Center (IDDRC)

The Eunice Kennedy Shriver Center

University of Massachusetts Medical School

Worcester, MA

Vice Chair 2008 - pres.

Department of Psychiatry

University of Massachusetts Medical School

Worcester, MA

Co-Director 2008 - pres.

Child and Adolescent Neurodevelopment Initiative (CANDI) Department of Psychiatry

University of Massachusetts Medical School

Worcester, MA

Director 1996 - 2004

Pediatric Psychotic Disorders Research Program

McLean Hospital, Belmont, MA

**Hospital Positions**

Attending in Child Psychiatry Outpatient Clinic 2008 - pres.

UMASS Memorial Medical Center, Worcester, MA

Courtesy Staff Psychiatrist 2008 - 2010

Cambridge Health Alliance, Cambridge, MA

Child Psychiatrist 2004 - 2008

Active Staff, Cambridge Health Alliance, Cambridge, MA

Attending in Child Psychiatry Outpatient Clinic 2004 - 2008

Cambridge Health Alliance, Cambridge MA

Staff Consultant to the McLean inpatient child and adolescent units 1996 - 2008

Franciscan Children’s Hospital, Brighton, MA

Attending in Child Psychiatry Outpatient Clinic 1996 - 2004

McLean Hospital, Belmont, MA

Attending in Child Outpatient & Joint Pediatric Psychopharmacology Program 1995 - 2003

Massachusetts General (Boston, MA) and McLean Hospitals (Belmont, MA)

Attending Psychiatrist in Outpatient Clinic 1995 - 1996

Chelsea Memorial Health Care Center (Massachusetts General Hospital affiliate), Chelsea, MA

Associate Child Psychiatrist 2001 - 2008

McLean Hospital, Belmont, MA

Staff Psychiatrist 1996 - 2008

McLean Hospital Unit, Franciscan Children’s Hospital, Brighton, MA

Clinical Assistant in Psychiatry 1996 - 2004

Massachusetts General Hospital, Boston, MA

Clinical Assistant in Psychiatry 1996 - 2001

McLean Hospital, Belmont, MA

Clinical Assistant in Psychiatry 1995 - 1996

Chelsea Memorial Health Center (MGH), Chelsea, MA

**Other Positions and Employment**

Laboratory Technician 1986 - 1987

Suburban Medical Laboratory, Cuyahoga Falls, OH

**Certification and Licensure**

Diplomate, American Board of Psychiatry and Neurology: 1994

Board Certification in Child and Adolescent Psychiatry

Diplomate, American Board of Psychiatry and Neurology: 1993

Board Certification in Adult Psychiatry

Rhode Island Medical License Registration 1991 - 1993

Massachusetts Medical License Registration 1989 - pres.

**Honors and Awards**

Distinguished Fellow, American Academy of Child and Adolescent Psychiatry 2016 - pres.

Women in Science and Health Achievements Award 2016

Women’s Faculty Committee, MMS

The American College of Neuropsychopharmacology, Fellow 2015 - pres.

Steven Banks Award for Research Mentoring 2013

Department of Psychiatry, UMass Medical School, Worcester, MA

Morley Medal for scientific achievement (Western Reserve Academy) 2013

Western Reserve Academy, Hudson OH

Paul F. Briscoli Award for Resident-Faculty Academic Collaboration 2012

Department of Psychiatry, UMass Medical School, Worcester, MA

Awarded jointly to Drs. David Cochran (*resident*) and Jean Frazier (*faculty*)

Top Doctors list in U.S. News & World Report 2012 - 2016

Best Doctors in America 2009 - 2016

Leadership Award 2007

STEP Up 4 Kids, Marshfield, MA

Outstanding Educator Award for Mental Health Education 2006

New England Educational Institute, Lenox, MA

Distinguished Fellow 2006

American Psychiatric Association

Outstanding Psychiatrist Award for Research 2003

Massachusetts Psychiatric Society

Annual Exemplary Psychiatrist Award 2002

National Alliance for the Mentally Ill

Partners in Excellence Award-as the Team leader for Child Psychiatry Outpatient 2000

In recognition for Excellent Clinical Service and Team Work

Partners Healthcare/McLean Hospital, Belmont, MA

Mentor Award 2000

MGH/McLean Hospital Child and Adolescent Psychiatry Fellows Boston, MA

Travel Award for American College of Neuropsychopharmacology 1999

Bristol Myer Squibb

Child and Adolescent Residency Teaching Award 1998

MGH/McLean Hospital Child and Adolescent Psychiatry Fellows, Boston, MA

Child and Adolescent Residency Teaching Award 1997

As part of the Pediatric Psychopharmacology Team

[Drs. Biederman, Spencer, Wilens, Frazier, Wozniak]

MGH/McLean Hospital Child and Adolescent Psychiatry Fellows, Boston, MA

Consultation Liaison Psychiatry Award 1995

National Institute of Mental Health, Bethesda, MD

Sandoz Neurology Award 1987

Dartmouth Medical School, Hanover, NH

Outstanding Young Women of America 1985

Wellesley College Scholar 1982

Wellesley College, Wellesley, MA

Freshman Honors 1979

Wellesley College, Wellesley, MA

English Speaking Union Scholarship 1978

Study in England for one year

**Professional Memberships and Activities**

International Society of Autism Research 2016 - pres.

The American College of Neuropsychopharmacology, Fellow 2015 - pres.

The International Society for Bipolar Disorders 2013 - pres.

International Early Psychosis Association, *Member* 2007 - 2008

The American College of Neuropsychopharmacology, *Full Member* 2008 - 2015

Society of Biological Psychiatry, *Member* 2007 - pres.

Sociedad de Psiquiatria y Neurologia de la Infancia y Adolescencia 2006 - pres.

In Chile, *Honorary Member*

National Foundation for Mental Health, *Member* 2004 - pres.

The American College of Neuropsychopharmacology, *Associate Member* 2002 - 2007

Massachusetts Psychiatric Association, *Member* 1996 - pres.

The American Society of Clinical Psychopharmacology, *Member* 1995 - pres.

Rhode Island Psychiatric Association, *Member* 1991 - 1996

American Academy of Child and Adolescent Psychiatry, Member 1991 - pres.

New England Council of Child and Adolescent Psychiatry, *Member* 1991 - pres.

Massachusetts Psychiatric Association, *Member* 1987 - 1991

American Medical Association, *Member* 1987 - 2007

American Psychiatric Association, *Member* 1987 - pres.

**Editorial Responsibilities**

*Editorial Boards*

Journal of the American Academy of Child and Adolescent Psychiatry 2016 - pres.

Neuropsychiatry Reviews 2008 - 2010

F1000 Prime - Medicine (*Faculty*) 2006 - 2009

Journal of Child and Adolescent Psychopharmacology 2006 - pres.

(*Associate Editor of Psychotic Disorders-ending 2015)*

*(Associate Editor of Autism Spectrum Disorders-beginning 2016)*

Harvard Review of Psychiatry (*Field Editor*) 2003 - pres.

*Ad Hoc Reviewer*

Molecular Psychiatry 2014 - pres.

Autism Research 2014 - pres.

Autism: International Journal of Research and Practice 2012 - pres.

Journal of Autism and Developmental Disorders 2012 - pres.

Journal of Abnormal Psychology 2011 - pres.

Pediatrics 2008 - pres.

Bipolar Disorder 2006 - pres.

Journal of Child Psychology and Psychiatry 2006 - pres.

Neuropsychopharmacology 2004 - pres.

Journal of Clinical Psychiatry 2003 - pres.

Journal of Pediatric Drugs 2003 - pres.

Biological Psychiatry 2002 - pres.

Schizophrenia Research 2002 - pres.

Journal of Child and Adolescent Psychopharmacology 2000 - pres.

Journal of the American Medical Association 2000 - pres.

Schizophrenia Bulletin 2000 - pres.

American Journal of Psychiatry 1999 - pres.

Archives of General Psychiatry 1995 - pres.

Journal of the American Academy of Child and Adolescent Psychiatry 1995 - pres.

**Educational Activities: Teaching**

**Teaching: *Leadership and Curriculum Development- Medical Students/Residents***

Master Clinician Psychopharmacology Seminar, *Director*, 2012 - pres. Department of Psychiatry

University of Massachusetts Medical School, Worcester, MA

(*Child Psychiatry Fellows (n=6), 1-hour monthly seminar*)

Child Psychopharmacology Course, *Course Director and Lecturer*, 2004 - 2008

Department of Psychiatry

Harvard Medical School, Boston, MA

(First Year child and adolescent psychiatry fellows (n=6),

1 hour teaching every week (50 hours) across the year)

Child Fellowship-Developmental Disabilities Seminar, 2001 - 2004

*Course Director and Lecturer*

Department of Psychiatry

McLean/Massachusetts General Hospital, Boston, MA

(First year child psychiatry fellows (n=6), 32 hours of teaching)

Psychopathology, *Small Group Leader* 1990 - 1991

Department of Psychiatry

Tufts University Medical School, Boston, MA

(6 Second year medical students, 1 hour teaching each week for 6 weeks)

**Teaching: *Didactics for Graduate Students/Medical Students/Residents***

**Didactics: Graduate Students**

University of Massachusetts Medical School, Worcester, MA

MDP 7400 Course with Graduate Students. Topic “What is the relationship 2015

between environmental and genetic determinants of autism?”

First year MD/PhD Students and students on Clinical Translational Research Pathway

One ½ lecture and 1-½ hour discussion of articles (n=@30)

3 additional sessions during which I served as faculty discussant

**Didactics: *Medical StuDecember 12, 2016dents***

University of Massachusetts Medical School, Worcester, MA

Mind, Brain and Behavior 2009 - pres.

Medical School Course in Psychiatry

Lecturer of two one-hour lectures (n=@100).

Plus 2 hours of running two small groups (n=@25).

Harvard Medical School, Boston, MA

Donald Cohen Fellowship for Child and Adolescent Psychiatry 2005 - 2008

Medical Student Mentoring, Cambridge Health Alliance, Cambridge MA

2 hours a month meeting with a medical student, 1 hour shared

Meeting with a patient and 1 hour informal discussion throughout the year

Medical Student Elective 2004 - 2005

Psychiatry, McLean Hospital, Belmont, MA

Taught one medical student at a time during elective time,

1 hour teaching each week throughout the year

Tufts University Medical School, Boston, MA

Mental Status Examination 1990 - 1991

Psychiatry Rotation Lecturer

Groups of 6-8 third year medical students during their psychiatry rotation

**Didactics*: Residents and Child Psychiatry Fellows***

University of Massachusetts Medical School, Worcester, MA

“Clinical Research In Child Psychiatry’, *Lecturer* 2015

Child Psychiatry Residents (n=6), 1 hour lecture

“Complementary and Alternative Medicines”, *Lecturer* 2015

Adult and Child Psychiatry Residents (n=10), 2 hour lecture

“Complementary and Alternative Medicines”, *Lecturer* 2014

Adult and Child Psychiatry Residents (n=10), 2 hour lecture

“Research in Child Psychiatry”, *Discussant* 2013

Hosted the child fellows from Yale at UMASS Worcester, MA (n=10),

4 hours contact

“Complementary and Alternative Medicines”, *Lecturer* 2013

Adult and Child Psychiatry Residents (n=10), 2 hour lecture

“Clinical Trials”, *Lecturer*, 2013

Adult and Child Psychiatry Residents (n=10), 2 hour lecture

“Master Clinician” Psychopharmacology Seminar, *Discussant*, 2012 - pres.

Department of Psychiatry

University of Massachusetts Medical School, Worcester, MA

(*Child Psychiatry Fellows (n=4), three 1-hour seminars*)

“Early Onset Psychosis”, *Lecturer,* 2012

Adult and Child Psychiatry Residents (n=10), 1 hour lecture

Neuropsychiatry Case Conference, *Discussant* 2012

Child Fellows & Pediatric Residents (n=20), 1-hour discussion

“Pediatric Bipolar Disorder”, *Lecturer*, 2012

Child Psychiatry Fellows (n=4), 1 hour lecture

“Autism” Child Psychiatry Fellow Journal Club. *Discussan*t, 2011

Child Psychiatry Fellows (n=4), 1 hour discussion.

“Early Onset Psychosis “Child Psychiatry Fellow Journal Club. 2011

*Discussant*, Child Psychiatry Fellows (n=4), 1 hour discussion.

“Clozapine*” Lecturer*, 2010

Child Psychiatry Fellows and Faculty (n=10) 1 hour lecture.

Child Psychiatry Seminar for 3rd year residents, *Lecturer*, 2009 - 2010

Adult Psychiatry Residents. (n=6) two 1-hour lectures.

Psychopharmacology Course. *Lecturer*, 2008 - 2009

Child and Adolescent Psychiatry Fellows (n=4), two 1 hour lectures

Harvard Medical School *Cambridge Health Alliance, Cambridge, MA*

“Neuroscience of Early-Onset Schizophrenia,” *Lecturer*, 2007 - 2008

Developmental Neuroscience Seminar. Children’s Hospital, Boston, MA

Harvard Second Year Child and Adolescent Psychiatry Fellows (n=20),

1 hour lecture.

“Pediatric Bipolar Disorder.” Seminar. *Lecturer*, 2006

Massachusetts Mental Health Boston, MA. Neuropsychology

Post Docs. (n=10), 1 hour contact.

“Pediatric Bipolar Disorder.” *Presenter* 2006

Psychopharmacology Seminar*,*

Adult Psychiatry Residents (n=14), 1 hour contact.

“Pediatric Psychotic Disorders.” *Presenter* 2006

Psychopathology Seminar*,*

Adult Psychiatry Residents (n=7), 1 hour contact.

“The Importance of Evidence,” *Panelist,* 2005

Harvard Psychiatry Residents’ Day Panelist,

Psychiatry Residents **(n=50) 6 hours on one day.**

“Pediatric Psychosis: What Have We Learned?” *Seminar Presenter*, 2005

Massachusetts Mental Health, Boston, MA Neuropsychology

Post Docs (n=10), 1 hour contact.

Harvard Medical School *McLean and Massachusetts General Hospitals, Boston, MA*

Psychopathology Course, *Lecturer* 2004 - 2008

Consolidated Dept. of Psychiatry, McLean Hospital

First year child fellows (n=20), 2 hours of teaching each year

Psychopharmacology Course, *Lecturer,* 2001 - 2004

Psychiatry Residents (n=8), 2 hours of teaching each year

Psychopathology Course, *Lecturer* 1999 - 2004

Consolidated Dept. of Psychiatry

First year Child Psychiatry fellows (n=20), 2 hours of teaching each year

Psychopathology Course, *Lecturer*, 1996 - 2004

Third Year Psychiatry Residents (n=8), 1 hour of teaching each year

Pediatric Psychopharmacology Course*, Lecturer*, 1996 - 2004

First year child and adolescent psychiatry fellows (n=6),

3 hours of teaching each year

Brown Medical School *Emma* *Pendleton Bradley Hospital, Providence, RI*

Psychopathology, *Lecturer*, 1993

First year Child Psychiatry fellows (n=6),Two 1 hour lecture each year

**Teaching: *Didactics*- *Peers and Colleagues***

UMASS Medical School

Neuroscience Retreat – “Neuroimaging correlates of social cognition in ASD” 2015

(faculty, post docs and grad students) 1 hour lecture

Neuroscience Seminar – “Neuroimaging correlates of social cognition in ASD” 2015

50 attendees (faculty, post docs and grad students) 1 hour teaching

National Institutes of Health, Bethesda

DSM IV / FAES course, *Lecturer*, 1995

30 course enrollees (medical professionals from various disciplines)

6 hours of teaching

**Teaching Activities: *Leadership and Curriculum Development/Continuing Medical Education, Conference Symposia and Institutes***

American Academy of Child and Adolescent Psychiatry Annual Meeting 2016

***Institute Co-Chair*** *with Dr. Veestra-VanderWeele for “Research Institute:*

*Epigenetics in Child and Adolescent Psychiatry.”*

New York, New York

Systems and Psychosocial Advances Research Center UMMS –Webinar Series 2016

**Webinar Presenter**: Comorbid Autism Spectrum Disorder (ASD)

and Serious Mental Illness (SMI)

American Academy of Child and Adolescent Psychiatry Annual Meeting 2013

***Institute Co-Chair*** *with Dr. Dvir*, for “*Psychotic Disorders in*

*Youth: Diagnostic and Treatment Considerations”*

Orlando, Florida

***Chair Presentation*** *for Symposium “Treatment of Emerging*

*Young Adults with Psychiatric Needs”*

National Network of Depression Centers Annual Conference 2013

Co-Chair Child and Adolescent Task Group. Symposium: “Childhood

Assessment of Mood Disorders”, Ann Arbor, MI

Asperger’s Association of New England: Annual Conference. 2011

*Member, Program Committee*.

2-day conference entitled: Sexuality, Relationships, and Asperger

Syndrome with presentations by Dr. Isabelle Henault

American Academy of Child and Adolescent Psychiatry - 34th Annual 2009

Review Course in Child and Adolescent Psychiatry and Training

Session for the Oral Boards.

*CME*-*Co-Chair with Drs. Weinstein and Wilens*.

The 4-day Course included lectures given by faculty from Harvard,

Tufts, BMC, and UMASS

Cambridge Hospital/Harvard Medical School. *CME Course Director*, 2008

“Bipolar Disorder” Two-day conference involving the following speakers:

Ghaemi N, Leibenluft E, Bauer MS, Reilly-Harrington N, Hunt J,

McDonnell M, Schultz J, Frazier JA, Youngstrom EA, Sachs G, Stoll AL, Moran PW,

Leeds M, Sweezy M, Zamvil L.

American College of Neuropsychopharmacology 46th Annual Meeting. 2007

*Chair of Panel* entitled “Treatment of Early Onset Schizophrenia Spectrum

Disorders” Speakers included: Frazier J, Sikich L, McClellan J, and Vitiello B.

Discussant: Lieberman J.

Cape Cod Symposium **Week Long Course**, “State of the 2007

Art Pediatric Psychopharmacology,” *Lecturer*, Topics included: Introduction to

psychopharmacology, aggression, anxiety, bipolar disorder, and

psychosis. Eastham, MA. **[organizer**]

American College of Neuropsychopharmacology 46th Annual Meeting 2007

*Chair of Panel* entitled: “Puberty, Sex, Brain and Behavior”

Speakers included: Goldstein JM, Smith SS, Bale T B, and Frazier JA

Discussant: Schmidt P.

American Academy of Child and Adolescent Psychiatry 54th Annual Meeting 2007

*Co-Director* with Bradley Peterson and Bennett Leventhal.

*Founders of the Research Initiative Symposium*: “Genetic and Epigenetic

Influence on Brain Development and Behavior, and Their Importance for

Understanding

Childhood Psychiatric Disorders.” Involving the following speakers:

Rubenstein J, Walsh C, Meaney M, and Lander E.

American Academy of Child and Adolescent Psychiatry 54th Annual Meeting 2007

*Chair of Symposium* entitled “Neuroimaging Findings in Bipolar Disorder

Across the Lifespan” Speakers included: Frazier J, DelBello M, Adler C,

Yurgelan-Todd D. Discussant: Renshaw P.

Cambridge Hospital/Harvard Medical School. *CME Course Director*, 2007

“Autism Spectrum Disorders: From Childhood to Adulthood.”

Two day conference involving the following speakers: Herbert MR, Rosenn D,

Frazier JA, Michaels A, Debbaudt D, Senator SL, Korin EH, Lucci D,

McLeod DS, Densmore A, Bolick T, Appelstein C, Weeks LK, Levine K.

Cambridge Hospital/Harvard Medical School. *CME Course Director* 2006

“Bipolar Disorder” Two day conference involving the following speakers:

Carlson G, Cohen BM, Berk SA, Ablon JS, Pauley J, Sklar P, Zamvil L,

Frazier JA, Beck JS, Walsh B, Desrosiers A, Duckworth K, Davis TM.

Cape Cod Symposium Week Long Course “State of the Art Pediatric 2006

Psychopharmacology.”

Topics included: Introduction to psychopharmacology, aggression, anxiety,

bipolar disorder, and psychosis. Eastham, MA**. [organizer]**

Cambridge Hospital/Harvard Medical School. *CME Course Director*, 2005

“Autism Spectrum Disorders: From Childhood to Adolescence.”

Two-day conference involving the following speakers: Bauman ML,

Frazier JA, Laurent AB, Lovass I, Dinklage D, Hirshberg LM, Greene S,

Rothenberg S, Greene S, Barrett RP, Bolick T, Hardy PM, Shore SM,

Prince JB, Chedd NA, Schlein T, Branconnier ME, Gabovitch EM, Blaxil MF.

Cape Cod Week Long Symposium. Topics included: Introduction to 2005

psychopharmacology, aggression, anxiety, bipolar disorder, and psychosis.

Eastham, MA. [**organizer**]

American Academy of Child and Adolescent Psychiatry 50th Annual 2003

Meeting. *Course director* of *an* ***All-day institute****.*

*Institute:* “Childhood major mental illness: New directions from bench to clinic.”

Involving the following speakers: Frazier JA, Carlson C, Carter, A, Pauls D,

Guiliano A, Holtzman D, Sikich L.

*Symposium:* “Childhood neuroimaging: Similarities and differences

between clinical samples and healthy subjects.”

Involving the following speakers: Frazier JA, Giedd J, Nicolson R, Sikich L,

Benes F.

Cape Cod Symposium Week Long Course “Treatment of Major Mental Illness 2003

in Children.”

Topics included: Introduction to psychopharmacology, mental retardation

and pervasive developmental disorders, major depression, bipolar disorder,

and psychosis. Eastham, MA.

Cape Cod Symposium Week Long Course “Treatment of Major Mental Illness 2002

in Children”

*Lecturer*: Topics included: Introduction to psychopharmacology, mental retardation

and pervasive developmental disorders, major depression, bipolar disorder, and

psychosis. Cape Cod Symposium, Eastham, MA

**Educational Activities: Advising and Supervision**

**Advising and Supervision: *Research***

University of Massachusetts Medical School, Worcester, MA

Mentor in Graduate Studies of Biomedical Sciences Program in 2011 - 2015

Clinical and Population Health Research

1 hour a week of individual supervision for one student

Mentor in the Senior Scholars Program 2010 - 2013

1 hour a week of individual supervision for each student involved.

2012 and 2013: 2 students

Child Psychiatry Division Research Mentor 2008 - pres.

Meet weekly on an individual basis with child fellows, medical students,

and junior faculty members involved in research in the child psychiatry division.

5 hours each week.

***Research Trainees***

Mollie Wood, GSBS student 2011 - 2015

4 years under my Supervision, UMASS Medical School

Thesis: “Causal Inference Methods for Assessing Neurodevelopment

in Children Following Prenatal Exposure to Triptan Medications”

Current Position: Postdoctoral Fellow at University of Oslo, Mentor

Hedvig Nordeng

Alisha Jaquith, Medical Student 2011

1 year under my supervision, UMASS Medical School,

Clinical Translational Track

Current Position: Second Year Child Psychiatry Fellow UMMS

Rashad Hardaway, Medical Student 2011

1 year under my supervision, UMASS Medical School, Clinical Translational

Track Current Position: PGY 5 Psychiatry resident Harvard Longwood Program

Wendy Marsh, M.D. 2011- 2013

2 years under my supervision, K awardee

Current Position: Director Bipolar Specialty Clinic

Associate Professor of Psychiatry UMMS

Gina Vincent, Ph.D. 2010 - 2015

5 years under my supervision, K awardee

Current Position: Director of Translational Law and Psychiatry Research

Associate Professor of Psychiatry, UMMS

Charmaine Lo. Member, Student Thesis Committee 2010

Thesis: “Methods to Assess Health Behaviors Associated with Risk of

Chronic Disease in Adolescents with Intellectual and Developmental

Disabilities: A Systematic Review.”

Current Position: Research at Blue Cross Blue Shield in Michigan

David Cochran, M.D., Ph.D. 2009 - pres.

7 years under my supervision

First as Child Psychiatry Resident and now as an Assistant

Professor in Psychiatry.

UMASS Medical School.

Current Position: Assistant Medical Director, Center of Autism and

Neurodevelopmental Disorders

Assistant Professor of Psychiatry UMMS

Daniel Fallon, M.D. 2009 - 2010

12 months under my supervision

Child Psychiatry Resident. UMMS.

Current Position: Residency Training Director University of South Florida

Assistant Professor of Psychiatry

Kamlyn Haynes, M.D. 2009 - 2011

16 months under my supervision

Junior Faculty

Current Position: Assistant Professor of Psychiatry UMMS

Yael Dvir, M.D. 2009 - pres.

7 years under my supervision.

Junior Faculty

Current Position: Director of Early Onset Mood and Psychosis Clinic

Assistant Professor in Child Psychiatry. UMMS

Ruth Gerson, M.D. 2008

2 months under my supervision.

Resident at Cambridge Health Alliance

Current Position: Director, Children’s Comprehensive

Psychiatry Emergency Program

Assistant Professor in Child Psychiatry, NYU.

Lauren Shin, M.D. 2005 - 2008

3 years under my supervision.

Child Fellow at Cambridge Health Alliance

Current Position: Assistant Professor in Pediatrics and Psychiatry at

Rush University

Medical Center in Chicago, Illinois.

Karleyton Evans, M.D., M.Sc. 2005 - 2006

5 months under my supervision

Travel Awardee of the ACNP Junior Faculty at MGH.

Mentor through the American College of Neuropsychopharmacology.

Current Position: Director, Laboratory for Neuroimaging of Anxiety and

Respiratory Psychophysiology

Assistant Professor of Psychiatry, Harvard Medical School

Mary Ahn, M.D. 2003 - 2016

13 years under my supervision,

Resident, Fellow and Junior Attending at MGH/McLean

Current Position: Director, Career Development and Research Office

Director of Child and Adolescent Psychiatry Fellowship Training,

Associate Professor of Psychiatry, UMASS Medical School, Worcester, MA

Melissa Lopez-Larsen, M.D. 2003 - 2008

5 years under my supervision,

Resident at MGH and Child Fellow at Cambridge Health Alliance

Current Position: Child and Adolescent Psychiatrist at University of Utah,

Assistant Professor in Psychiatry,

Assistant Investigator in the USTAR and Brain Institute.

Anthony Giuliano, Ph.D. 2002 - 2005

3.5 years under my supervision

Massachusetts Mental Health Center Public Psychiatry Division

of the Beth Israel Deaconess Medical Center. Instructor in Psychology,

Harvard Medical School

Sandra DeJong, M.D. 2000 - 2004

3.5 years under my supervision

Child Fellow and Resident, MG

Current Position: Training Director, Child and Adolescent Psychiatry, Cambridge Health Alliance.

Assistant Professor of Psychiatry, Harvard Medical School

**Advising and Supervision: *Clinical***

UMASS Medical School *UMASS Memorial Health Care, Worcester, MA* 2013 - pres.

1 hour Weekly Supervision with Dr. Kadlec (Program Director) and

Dr. Cochran (Assistant Medical Director) of the Center for Autism and

Neurodevelopmental Disorders (CANDO)

UMASS Medical School *UMASS Memorial Health Care, Worcester, MA* 2008 - pres.

1 hour Weekly Supervision with Dr. Beheshti who oversees the Child Clinical

Services including Child EMHS and C/L Services.

UMASS Medical School *UMASS Memorial Health Care, Worcester, MA* 2008 - 2015

1.5 hour quarterly meeting with the entire UMASS MCPAP team.

UMASS Medical School *Worcester Recovery Center and Hospital, Worcester, MA* 2008 - 2015

*(formerly Worcester State Hospital)*

Attending Psychiatrists and Child Psychiatry Fellows at WRCH.

1 hour meeting per month with the entire group.

1 hour supervision per week with Dr. Tony Jackson (Medical Director)

and Caroline McGrath (Executive Director).

Harvard Medical School *Cambridge Health Alliance, Cambridge, MA*

Medical Student Mentoring 2005 - 2008

Donald Cohen Fellowship for Child Psychiatry at Cambridge Health Alliance

2 hours a month meeting with a medical student, 1 hour shared

meeting with a patient and 1 hour informal discussion throughout the year

Child Psychopharmacology Supervision 2004 - 2008

Meet weekly with 3 second year child psychiatry fellows to teach

psychopharmacology and to supervise cases

Cambridge Health Alliance

3 hours each week throughout the year.

Psychopharmacology Supervision 2004 - 2008

Cambridge Health Alliance

Child and Adolescent Psychiatry Fellows and Attendings (n=15)

1 hour each month throughout the year

Harvard Medical School *Massachusetts General and McLean Hospitals, Boston, MA*

Psychopharmacology Supervision 1996 - 2004

Inpatient Child and Adolescent Psychiatrists (n=3)

McLean inpatient Program/Franciscan Children’s Hospital

1 hour each week throughout the year.

Psychopharmacology Supervision 1996 - 2003

Second year MGH Child and Adolescent Psychiatry Fellows

Week (n=6), 3 hours each week throughout the year

Tufts Medical School, Boston, MA

Second and third year Tufts Medical School Psychiatry Residents 1990 - 1991

2 hours each week throughout the year

***Other Trainees/Supervisees***

Mary Ahn, M.D. 2009 - pres.

7 years under my supervision for her role as

Director of Child and Adolescent Psychiatry Fellowship Training,

Associate Professor in Psychiatry, UMASS Medical School, Worcester, MA

Scott Rodgers, M.D. 1998 - 2000

2 years under my supervision.

Current Position: Professor and Chairman, Department of Psychiatry

University of Mississippi Medical Center

Steven Schlozman, M.D. 1998 - 2000

2 year under my supervision on staff MGH

Current Position: Associated Director, The lay Center for Young Healthy Minds,

Assistant Professor of Psychiatry, Massachusetts General Hospital, Harvard Medical

School

Karen Monroe, M.D. 1997 - 2005

7 years under my supervision

Current Position: Director Child Outpatient Clinic, McLean Hospital;

Clinical Instructor in Psychiatry, Harvard Medical School

**Research Funding: (Federal, Institutional, Industry, Foundation) and Development/Fundraising**

**Initiatives**

**Grants and Contracts**

***Current Federal Grants- NIH***

Funding Agency: NIH/NICHD 9/21/16-8/31/23

Project Number: 1UG3OD023348-01 9/21/16-8/31/18 G3

Principal Investigator: Michael O’Shea UNC

Title: Environment, Epigenetics, Neurodevelopment & Health of

Extremely Preterm Children

Projected Costs:

Direct Costs: $1,875,886.00

Indirect Costs: $1,266,222.00

Total Costs: $3,142,108.00

Direct Costs for UMass Site UG3 Phase: $98,247 2016-2017

Indirect Costs for UMass Site UG3 Phase: $66,317

Total Costs for UMASS Site UG3 Phase: $164,564 2016-2017

Role: Site PI and lead on clinical phenotyping

Percent Effort: 20% year 1 and 40% years 2-7

Funding Agency: NIH/NLM 7/1/14-6/30/16

no cost ext

Project Number: 5R01 MH083320-06S1

Principal Investigator: Jean A. Frazier MD/David N. Kennedy PhD

Title: A Knowledge Environment for Neuroimaging in Child Psychiatry

Direct Costs: $41,577

Indirect Costs: $24,822

Total Costs: $66,355

Role: PI (multi-PI)

Funding Agency: NIH/NIMH

Project Number: 5R01 MH083320-08 (funded 8/1/09-8/30/16 also) 9/1/16-8/31/21

Principal Investigator: Jean A. Frazier MD/David N. Kennedy PhD

Title: Exposing the Deep Content of the Publication

Knowledge Extraction for Neuroimaging in

Child Psychiatry

Direct Costs: $2,058,863.00

Indirect Costs: $1,146,374.00

Total Costs: $3,205,237.00

Role: PI (multi-PI)

Percent Effort: 20%

***Current Contracts***

*Note: Clinical Trials are typically awarded with a contracted maximum award, determined by the contracted enrollment cap. Total awards therefore are dependent upon enrollment. Total contracted award is listed*.

Funding Agency                                Roche TCRC, Inc. (Roche)                       11/2/2016-10/31/2018

Project Number:

Site PI:                                             Jean A. Frazier MD

Title:                                                 A Phase II Multi-Center Randomized, Double-blind,

3-ARM, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of R05285119 in Children and Adolescents age 5-147 with Autism Spectrum Disorder (ASD)

Projected Costs:

Direct Costs                                     $17,178

Indirect Costs                                   $  5,153

Total Costs                                       $22,331

Role:                                                 Site PI (UMMS)

Funding Agency: SyneuRX International Corp. 9/1/14-12/31/16

Project Number: SNR01NaBen/CT140008

Site PI: Jean A. Frazier MD

Title: An Adaptive, Phase IIb/III, Double-Blind,

Randomized, Placebo-Controlled,

Multi-Center Study of the Safety and

Efficacy of NaBen® (sodium benzoate),

a D- Amino Acid Oxidase Inhibitor, as an

Add-on Treatment for Schizophrenia in Adolescents

Projected Costs:

Direct Costs: $68,618

Indirect Costs: $20,585

Total Costs: $89,204

Role: Site PI (UMass)

***Current Grants- UMass***

None

***Current Grants-Foundations***

Funding Foundation: Autism Consortium Family Support 2009-2016

Project Number: UMM-002-00070-03

Principal Investigator: Jean A. Frazier, M.D

Total Costs $ 15,236.83 (2009)

$ 45,170.78 (2010)

$ 47,186.28 (2011)

$ 47,393.43 (2012)

$ 45,519.00 (2013)

$ 43,833 (2014)

$22,486 (2015)

$30,082 (2016)

------------------------

Total Costs: $296,907.32 to date

**Grants: *Pending***

***Pending Federal Grants – NIH***

Funding Agency: NIH Submission Date June 2016 –

Project Number: R01

Principal Investigator: Jean A. Frazier MD and Robert Althoff, M.D.

Title: Mood-Behavior Dysregulation in youth:

cognitive control

Costs: *not yet available*

Role: PI (multPI)

Funding Agency: NIH Submission Date June 2016 –

Project Number: K23 Award

Principal Investigator: David Cochran MD, PhD

Title: Imaging Biomarkers of Social Cognition

and Treatment Response in Autism

Costs: *not yet available*

Role: Mentor

***Pending Grants – UMass/Foundation***

*None at present*

***Pending Contracts:***

Funding Agency: Janssen Research & Development 11/01/16 –

Project Number: 42165279AUT2001

Site PI: Jean A. Frazier MD

Title: “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group,

Multicenter Study Investigating the Efficacy, Safety, and Tolerability

of JNJ-42165279 in Adolescent and Adult Male Subjects with Autism Spectrum Disorder”

Direct Costs:

Indirect Costs:

Total Costs:

Role: Site PI (UMass)

***Completed Grants- NIH***

Funding Agency: NIH/NINDS 9/15/11-08/31/15

Project Number: 5U01NS040069-08

Principal Investigator: Karl Kuban MD

(*Boston Medical Center, Boston, MA*)

Title: Neonatal Biomarkers in Extremely Preterm

Babies Predict Childhood Brain Disorders

Direct Costs: $ 9,278,084 (*approximate calc., FY2011 breakdown NA*)

Indirect Costs: $ 1,321,948 (*approximate calc., FY2011 breakdown NA*)

Total Costs: $10,600,032(total across ***all*** sites, FY 2011-2013)

Role: Site PI (UMass)

Percent Effort: 10%

Funding Agency: NIH/NICHD (Dr. Frazier’s involvement) 8/1/10-6/30/15

*Project has long funding history* 8/1/97-6/30/15

Project Number: 5P30 HD004147-39

Principal Investigator: William McIlvane, PhD

Title: Intellectual and Developmental Disabilities

Research Center Direct Costs:

$497,221 (*total across cores for current year*) Indirect Costs: $320,708 (*total across cores for current year*)

Total Costs: $817,929 (*total across cores for current year*)

Role: Center Co-Director, IDDRC (Associate Director on previous cycle)

Co-Director (Core A) Administration Communications and Mentorship

(Core D- on previous cycle, only 3 cores current cycle)

Percent Effort: 12.5%

Funding Agency: NIH/NIDA 9/30/09-8/31/11

*Includes 1 yr. no cost extension*

Project Number: 1RC2DA029475-01

Principal Investigator: Terry Jernigan PhD *UCSD*

Title: Creating a Pediatric Imaging-Genomics Data Resource

Direct Costs: $184,969

Indirect Costs: $119,150

Total Costs: $304,119

Role: Site PI (UMass)

Funding Agency: NIH/NIMH 9/1/07-8/31/12

*My involvement*: 2007-2008

Project Number: 1P50 MH080272 (CIDAR)

Principal Investigator: Robert McCarley, MD

(Beth Israel Deaconess Medical Center, Boston MA)

Title: Longitudinal Assessment and Monitoring of Clinical

Status and Brain Function in Adolescents and Adults

Direct Costs: $ 1,200,000 (annual directs across projects)

Indirect Costs: $ 800,000 (annual indirects across projects)

Total Costs: $10,000,000 (sum total across projects)

Role: Investigator, Project 2

Senior Consultant on Psychosis in Adolescents

and Young Adults

Site PI: (Cambridge Health Alliance)

Funding Agency: NH/NIMH 2001-2007

Project Number: U01 MH62726

(each investigator awarded separately)

Principal Investigator: Jeffrey Lieberman, Overarching PI

(*UNC/Chapel Hill, NC*)

Title: Treatment of Early Onset Schizophrenia

and Schizoaffective Disorders

Total Costs: $1,708,732 (Harvard Site)

Role: PI

Funding Agency: NIMH 7/1/98-6/30/04

Project Number: K08 MH01573

Principal Investigator: Jean A. Frazier, MD

Title: Brain Anatomic MRI in Childhood Bipolar Disorder

Co-Mentors: Verne Caviness, MD, D Phil, Joseph Biederman MD

Total Costs: $743,836

Role: PI

***Completed Contracts***

***NIH-sponsored Clinical Trials- completed***

Funding Agency: IH/NICHD 5/1/09-4/30/13

Project Number: HHSN275200503406C

Principal Investigator: Robert Findling MD (Case Western Reserve)

Title: Best Pharmaceuticals for Children Act

Pediatric Off-Patent Drug Study (PODS):

Lithium for the Treatment of Pediatric Mania

Total Costs: $1,216,252

Role: Site PI (UMass)

Funding Agency: NIH/NICHD 2005-2008

Project Number: HHSN275200503406C

Principal Investigator: Robert Findling MD

(Case Western Reserve, Cleveland, OH)

Title: Best Pharmaceuticals for Children Act

Pediatric Off-Patent Drug Study (PODS):

Lithium for the Treatment of Pediatric Mania

Total Costs: *not available*

Role: Site PI (Cambridge Health Alliance

**Completed Grants-UMASS**

Funding Agency: UMass CTSA designee 4/1/13-3/31/15

Project Number: NIH 5 UL1 RR0000161-04

(*NIH award to UMass*) (no cost extension)

Principal Investigator: Jean A. Frazier MD/Joel Richter PhD

Title: Amelioration of the Fragile X Syndrome

(FXS) By Targeting the Translational Apparatus

Direct Costs: $34,628 *to date*

Indirect Costs: NA

Total Costs: $34,628

Role: Co-PI

Percent Effort: 1.33%

***Industry Sponsored Clinical Trials-completed***

Funding Agency name: Janssen Research & Development 7/1/15-6/30/16

Project Number: Mentis Protocol ASD-002

Project Title: A Study to Assess the Janssen Autism

Knowledge Engine in Children and Adults

with Autism Spectrum Disorder and in a

Normally Developing Cohort

Projected Costs:

Direct Costs: $ 59,506

Indirect Costs: $ 17,852

Total Costs: $ 77,357

Role: Site PI

Funding Agency: Neuren Pharmaceuticals, Ltd. 4/16/14-4/15/15

Project Number: Neuren Pharmaceuticals NNZ-2566

Principal Investigator: Jean A. Frazier MD

Title: A Randomized, Double-Blind,

Placebo-Controlled, Parallel Group, Fixed-Dose

Study of NNZ-2566 in Fragile X Syndrome

Direct Costs: $198,287

Indirect Costs: $ 57,431

Total Costs: $255,718

Role: Site PI

Funding Agency: Hoffman LaRoche Inc. 2/4/13-2/28/14

Project Number: HOFFMAN-LA ROCHE INC-CT 1300038

Principal Investigator: Jean A. Frazier MD

Title: A Randomized, Parallel Group, Double-Blind,

Placebo-Controlled, Safety, and Exploratory,

Efficacy and Pharmacokinetic Study of R04917523

in Pediatric Patients with Fragile X Syndrome-

Protocol NP28571

Direct Costs: $ 65,940

Indirect Costs: $ 19,780

Total Costs: $ 85,720

Role: Site PI

Funding Agency: Hoffman LaRoche Inc. 6/12/12-3/1/13

Project Number: HOFFMAN/Protocol NP27936/CT-1200088

Principal Investigator: Jean A. Frazier MD

Title: Controlled Study of the Efficacy and Safety

of R04917523 in Patients with Fragile X Syndrome

– Protocol NP27936

Direct Costs: $152,790

Indirect Costs: $ 35,260

Total Costs: $185,080

Role: Site PI

Funding Agency: Seaside Therapeutics 12/6/11-9/30/13\*

Project Number: SEASIDE/209AS209-CT 1200023

Principal Investigator: Jean A. Frazier MD

Title: An Open-Label Extension Study to Evaluate

the Safety, Tolerability, and Pharmacokinetics

of STX209 (Arbaclofen) in subjects with Autism

Spectrum Disorders.

Direct Costs: $ 96,723

Indirect Costs: $ 29,107

Total Costs: $125,740

Role: Site PI

Funding Agency: Seaside Therapeutics 12/6/11-9/30/13\*

Project Number: SEASIDE/209FX303-CT 1200024

Principal Investigator: Jean A. Frazier MD

Title: An Open-Label Extension Study to Evaluate

the Safety, Tolerability, and Pharmacokinetics

of STX209 (Arbaclofen) in subjects with Fragile

X Syndrome.

Direct Costs: $133,046

Indirect Costs: $ 39,914

Total Costs: $172,960

Role: Site PI

Funding Agency: Seaside Therapeutics 9/28/11-9/30/13\*

Project Number: Seaside Therapeutics/ CT-1200031

Principal Investigator: Jean A. Frazier MD

Title: GABA concentrations with MRI spectroscopy

in ASD patients enrolled in Arbaclofen Trial

Direct Costs: $ 9,200

Indirect Costs: $ 2,392

Total Costs: $11,592

Role: Site PI

Funding Agency: Seaside Therapeutics 5/2/11-9/30/13\*

Project Number: Seaside Therapeutics\CT1100051

Principal Investigator: Jean A. Frazier MD

Title: A Randomized, Double-Blind, Placebo-Controlled

Study of the Efficacy, Safety, and Tolerability

of STX209 (Arbaclofen) Administered for the

Treatment of Social Withdrawal in Children with

Fragile X Syndrome. Protocol 209FX302

Direct Costs: $ 67,730

Indirect Costs: $ 20,319

Total Costs: $ 88,049

Role: Site PI

Funding Agency: Glaxo Smith Kline 7/31/08-0/26/11

Project Number: GSK\CT900004

Principal Investigator: Jean A. Frazier MD

Title: The Evaluation of LAMICTAL as an

Add-On Treatment for Bipolar I Disorder in

Children and Adolescents, 10 to 17 Years of Age

Direct Costs: $262,079.62

Indirect Costs: $ 68,140.70

Total Costs: $330,220.32

Role: Site PI

Funding Agency: Pfizer 2008-3/31/14

Project Number: Pfizer/Yale Univ/Zip Agreement/CT900013

Principal Investigator: Scott Woods, MD *Yale University, New Haven, CT*

Title: Ziprasidone vs Placebo in the Prevention

of Psychosis among Symptomatic Adolescents

and Adults at Prodromal Risk (“ZIP”)

Total Costs: $34,688 (yr1) + $69,389 (yr2) UMass site

Role: Site PI

***Note: for closed contracts prior to 2008 (prior to UMass), some details are not available***

Funding Agency: Neuropharm 2007-2008

Site Principal Investigator: Jean A. Frazier MD

Title: Oral Disintegrating Table of Fluoxetine

in Autism Spectrum Disorders

Role: Site PI (Cambridge Health Alliance)

Costs: *not available*

Funding Agency: Bristol Myer-Squibb/ Otsuka 2005-2007

Pharmaceuticals

Site Principal Investigator: Jean A. Frazier MD

Title: Open Label Trial of Aripiprazole in

Youths with Autism Spectrum Disorders

Role: Site PI (Cambridge Health Alliance)

Costs: *not available*

Funding Agency: Bristol Myer-Squibb/Otsuka 2005-2006

Pharmaceuticals

Site Principal Investigator: Jean A. Frazier MD

Title: Open Label Extension Trial of

Aripiprazole in Youths with Schizophrenia

and Bipolar Disorder

Role: Site PI (Cambridge Health Alliance)

Costs: *not available*

Funding Agency: Bristol Myer-Squibb/ Otsuka 2005-2006

Pharmaceuticals

Site Principal Investigator: Jean A. Frazier MD

Title: Double-Blind Trial of Aripiprazole

in Youths with Bipolar Disorder

Role: Site PI (Cambridge Health Alliance)

Costs: *not available*

Funding Agency: Pfizer 2005-2006

Site Principal Investigator: Jean A. Frazier MD

*4-site collaborative project with UNC,*

*Case Western Reserve,*

*University of* *Seattle, and Harvard*

Title: Ziprasidone open trial treatment of early onset

schizophrenia and schizoaffective disorder

Role: Site PI (Harvard Medical School)

Costs: *not available*

Funding Agency: Eli Lilly 1997-1998

Site Principal Investigator: Jean A. Frazier MD

Title: Olanzapine Treatment in Juvenile Mania

Role: Site PI (Massachusetts General Hospital)

Costs: *not available*

***Completed Grants – UMass***

Funding Source: Assumption College/UMMS

Dept. Psychiatry 2013-2014

CPRP Program

Principal Investigator: Jean A. Frazier MD / Paula Fitzpatrick MD

Title: Evaluating Social Synchrony in Autism

Spectrum Disorders

Total Costs: $7,500

Role: Co-PI

Funding Agency: UMass Life Sciences Moment Fund 2009-2011

Project Number:

Principal Investigator: Frazier/Davis/Kiernan

Title: Customized Employment and Training

Model-A Work Model Experience for

Transition Age Youth with Asperger’s Disorder

Direct Costs: $150,000

Indirect Costs: none

Total Costs: $150,000

Role: Co-PI

***Completed Grants – Foundations***

Funding Source: Simmons Foundation through the

Autism Consortium 2014-2015

Site Principal Investigator: Jean A. Frazier, M.D.

Title: Discovering Biomarkers in Autism

Total Costs: $32,112.78 (year1)

$37,096.24 (year 2)

Funding Source: SHINE-Anonymous Donor-UMass Sept. 2014

Department of Psychiatry Collaborative

Research Program

Principal Investigator: Constance Moore, PhD

Title: Investigation of Youth at Risk for Developing

Bipolar Disorder: A Multi-modal Neuroimaging Study

Total Costs: $10,000

Role: Co-PI

Funding Foundation: Private Family Foundation 2009-2011

Principal Investigator: Jean A. Frazier, MD

Title: Hormonal Influences on Frontolimbic

Neuromaturation in Girls with Bipolar Illness

Direct Costs: $ 98,148 (year 1)

$100,467 (year 2)

Total Costs: $198,615

Funding Foundation: Boston Autism Consortium 2006-2008

Site Principal Investigator: Jean A. Frazier, MD

Title: The Genetics of Autism

Role: Site PI (Cambridge Health Alliance)

Funding Foundation: Stanley Medical Research Institute 2005-2007

Principal Investigator: Bruce Cohen MD, PhD

Title: Adjunctive Taurine Treatment in Pediatric

Bipolar Disorder

Role: Co-I (Cambridge Health Alliance/McLean Hospital)

Costs: not available

Funding Foundation: Private Family Foundation 2004-2008

*Donation to Cambridge Health Alliance*

Principal Investigator: Jean A. Frazier, MD

Title: Imaging Study Staff Support

Role: PI

Costs: not available

Funding Foundation: Private Family Foundation 2004-2008

*Donation to Cambridge Health Alliance*

Principal Investigator: Jean A. Frazier, MD

Title: Longitudinal MRI Study of Psychotic Youths

Role: PI

Costs: not available

Funding Foundation: Private Family Foundation 2002-2008

*Donation to McLean Hospital/Cambridge*

*Health Alliance*

Principal Investigator: Jean A. Frazier, MD

Title: At Risk Study for Children with a First-

Degree Relative who Suffers from Psychosis

or Bipolar Disorder with Psychotic Features

Role: PI

Costs: not available

Funding Foundation: Private Family Foundation 2001-2008

*Donation to McLean Hospital /Cambridge*

*Health Alliance*

Principal Investigator: Jean A. Frazier, MD

Title: Longitudinal MRI study in Children with

Bipolar Disorder and Psychotic Disorders

Role: PI

Costs: not available

Funding Foundation: Private Family Foundation 2000-2003

*Donation to McLean Hospital*

Principal Investigator: Jean A. Frazier, MD

Title: Child Clinical Neuroscience Fellowship

Role: Mentor

Costs: not available

Funding Foundation: Private Family Foundation 2000-2003

*Donation to McLean Hospital*

Principal Investigator: Jean A. Frazier, MD

Title: Case Management Protocol for

Adolescent Outpatients with Mood Disorders

Role: PI

Costs: not available

Funding Foundation: Snyder Family Foundation 1999-2005

*Donation to McLean Hospital*

Principal Investigator: Jean A. Frazier, MD

Title: Brain Anatomic MRI in Children with

Mood Disorders with Psychotic Features

Role: PI

Costs: not available

Funding Foundation: Goldhirsh Foundation 1999-2004

*Donation to McLean Hospital*

Principal Investigator: Jean A. Frazier, MD

Title: Brain Anatomic MRI in Children

with Psychotic Disorders

Role: PI

Costs: not available

Funding Foundation: American Academy of Child and

Adolescent Psychiatry 1996-1997

Eli Lilly Pilot Research Award - Research

Principal Investigator: Jean A. Frazier, MD

Title: Functional magnetic resonance imaging

of attention in young adults with attention

deficit hyperactivity disorder

Role: Mentored Investigator

Mentor: Joseph Biederman, MD

Costs: not available

Site: Massachusetts General Hospital

***Clinical Contracts/Grants:***

**Adolescent Continuing Care Unit 1**

This is a long standing contract with MA Department of Mental

Directs and Indirects provided for Fiscal Years 2013-2015, and are approximately representative per annum since FY 2010.

Contracting Agency: MA Department of Mental Health 7/1/14-6/30/15

Grant Number: MA DMH/CCU 1-FY15

Project Title: Adolescent Continuing Care Unit 1

Direct Costs: $3,675,264

Indirect Costs: $ 463,077

Role: PI

Grant Number: MA DMH/CCU 1-FY14 7/1/13-6/30/14

Project Title: Adolescent Continuing Care Unit 1

Direct Costs: $3,741,491

Indirect Costs: $ 471,428

Role: PI

Grant Number: MA DMH/CCU 1-FY13 7/1/12-6/30/13

Project Title: Adolescent Continuing Care Unit 1

Direct Costs: $3,543,103

Indirect Costs: $ 446,010

Role: PI

Grant Number: MA DMH/CCU 1-FY12 7/1/11-6/30/12

Project Title: Adolescent Continuing Care Unit 1

Direct Costs: $3,486,103

Indirect Costs: $ 439,249

Role: PI

Grant Number: MA DMH/CCU 1-FY11 7/1/10-6/30/11

Project Title: Adolescent Continuing Care Unit 1

Direct Costs: $3,527,639

Indirect Costs: $ 419,047

Role: PI

Grant Number: MA DMH/CCU 1-FY10 7/1/09-6/30/10

Project Title: Adolescent Continuing Care Unit 1

Direct Costs: $3,460,525

Indirect Costs: $ 436,026

Role: PI

**Adolescent Continuing Care Unit 2**

This is a long standing contract with MA Department of Mental

Directs and Indirects provided for Fiscal Years 2013-2015, and are approximately representative per annum since FY 2010.

Contracting Agency: MA Department of Mental Health 7/1/14-6/30/15

Grant Number: MA DMH/CCU 2-FY15

Project Title: Adolescent Continuing Care Unit 2

Direct Costs: $3,518,217

Indirect Costs: $ 443,295

Role: PI

Grant Number: MA DMH/CCU 2-FY14 7/1/13-6/30/14

Project Title: Adolescent Continuing Care Unit 2

Direct Costs: $3,686,585

Indirect Costs: $ 464,510

Role: PI

Grant Number: MA DMH/CCU 2-FY13 7/1/12-6/30/13

Project Title: Adolescent Continuing Care Unit 2

Direct Costs: $3,412,690

Indirect Costs: $ 429,939

Role: PI

Grant Number: MA DMH/CCU 2-FY12 7/1/11-6/30/12

Project Title: Adolescent Continuing Care Unit 2

Direct Costs: $3,409,758

Indirect Costs: $ 429,629

Role: PI

Grant Number: MA DMH/CCU 2-FY11 7/1/10-6/30/11

Project Title: Adolescent Continuing Care Unit 2

Direct Costs: $3,366,810

Indirect Costs: $ 398,782

Role: PI

Grant Number: MA DMH/CCU 2-FY10 7/1/09-6/30/10

Project Title: Adolescent Continuing Care Unit 2

Direct Costs: $3,299,696

Indirect Costs: $ 415,762

Role: PI

**Behavioral Intensive Residential Treatment Program**

Contracting Agency: MA Department of Mental Health

Grant Number: MA DMH/BIRTP-FY14 7/1/13-1/30/14

Project Title: Behavioral Intensive Residential Treatment Program

Direct Costs: $1,560,261

Indirect Costs: $ 188,458

Role: PI

Grant Number: MA DMH/BIRTP-FY13 7/1/12-6/30/13

Project Title: Behavioral Intensive Residential Treatment Program

Direct Costs: $2,588,674

Indirect Costs: $ 326,173

Role: PI

Grant Number: MA DMH/BIRTP-FY12 7/1/11-6/30/12

Project Title: Behavioral Intensive Residential Treatment Program

Direct Costs: $2,760,179

Indirect Costs: $ 347,782

Role: PI

Grant Number: MA DMH/BIRTP-FY11 7/1/10-6/30/11

Project Title: Behavioral Intensive Residential Treatment Program

Direct Costs: $2,540,584

Indirect Costs: $ 314,850

Role: PI

Grant Number: MA DMH/BIRTP-FY10 7/1/09-6/30/10

Project Title: Behavioral Intensive Residential Treatment Program

Direct Costs: $2,508,808

Indirect Costs: $ 316,110

Role: PI

**Intensive Residential Treatment Program**

Grant Number: MA DMH/IRTP-FY14 7/1/13-1/30/14

Project Title: Intensive Residential Treatment Program

Direct Costs: $1,662,354

Indirect Costs: $ 201,421

Role: PI

Grant Number: MA DMH/IRTP-FY13 7/1/12-6/30/13

Project Title: Intensive Residential Treatment Program

Direct Costs: $2,858,959

Indirect Costs: $ 360,229

Role: PI

Grant Number: MA DMH/IRTP-FY12 7/1/11-6/30/12

Project Title: Intensive Residential Treatment Program

Direct Costs: $2,912,530

Indirect Costs: $ 366,979

Role: PI

Grant Number: MA DMH/IRTP-FY11 7/1/10-6/30/11

Project Title: Intensive Residential Treatment Program

Direct Costs: $2,548,141

Indirect Costs: $ 315,679

Role: PI

Grant Number: MA DMH/IRTP-FY10 7/1/09-6/30/10

Project Title: Intensive Residential Treatment Program

Direct Costs: $2,505,379

Indirect Costs: $ 315,678

Role: PI

**Clinical Funding: *Development/Fundraising Initiative***

In addition to the above-mentioned funding awards from Federal, industry and private organizations obtained to support my research endeavors, I have also been dedicated to the creation of an integrated outpatient clinic at UMASS, to better serve individuals with autism and other neurodevelopmental disorders, the Center for Autism and Neurodevelopmental Disorders (CANDO clinic). In 2013 we launched a development campaign to raise funds to support the CANDO program, and have raised **$2,111,000 dollars** to date.

Funding Source: Development Campaign 2013-pres.

Private

Purpose: *Program Support* for the recently

launched (2013)

**C**enter for **A**utism and **N**eurodevelopmental

**D**isorders

(CANDO clinic, UMASS)

Campaign/Organizer: Jean A. Frazier, M.D. with the support of

UMASS Development Office

Funds to Date: $2,111,000.00

**Publications**

**Peer-reviewed publications**

Original Articles

1. **Frazier JA**, Gordon CT, McKenna K, Lenane M, Jih D, Rapoport JL. An open trial of clozapine in 11 adolescents with childhood onset schizophrenia. Journal of the American Academy of Child & Adolescent Psychiatry 1994; 33:658-63. PMID: 8056728
2. Piscitelli SE, **Frazier JA**, McKenna K*, Albus K*, Grothe DR, Gordon CT, Rapoport JL. Clozapine and haloperidol plasma concentrations in adolescents with childhood-onset schizophrenia: association with response. Journal of Clinical Psychiatry 1994; 55(Suppl B):94-7. PMID: 7961584
3. Gordon CT, **Frazier JA**, McKenna K, Giedd J, Zametkin A, Zahn T, Hommer D, Hong W, Kaysen D, *Albus K*, Rapoport JL. Childhood-onset schizophrenia: neurobiologic characterization and pharmacologic response. An NIMH study in progress. Schizophrenia Bulletin 1994; 20:697-712.
4. Alaghband-Rad J, McKenna K, Gordon CT, *Albus KE,* Hamburger SD, Rumsey JM, **Frazier JA**, Lenane MC, Rapoport JL. Childhood-onset schizophrenia: the severity of premorbid course. Journal of the American Academy of Child & Adolescent Psychiatry 1995; 34:1273-83. PMID: 7592264
5. Jacobsen LK, Giedd JN, Vaituzis C, Hamburger SD, Rajapakse JC, **Frazier JA**, Kaysen D, Lenane M, Rapoport JL. Temporal lobe morphology in childhood onset schizophrenia. American Journal of Psychiatry 1996; 153:355-61. PMID: 8610822
6. **Frazier JA**, Giedd J, Kaysen D, Albus K, Alaghband-Rad J, Lenane M, Breier A, Rapoport J. Childhood onset schizophrenia: brain MRI rescan after two years of clozapine maintenance. American Journal of Psychiatry 1996; 153:564-6. PMID: 8599409
7. **Frazier JA**, Giedd J, Hamburger SD, *Albus K*, Kaysen D, Vaituzis C, Rajapakse JC, Lenane MC, McKenna K, Jacobsen L, Gordon CT, Breier A, Rapoport JL. Brain anatomic magnetic resonance imaging in childhood onset schizophrenia. Archives of General Psychiatry 1996; 53:617-24. PMID: 8660128
8. Jacobsen LK, Hong W, Hommer D, Castellanos F, **Frazier JA**, Giedd JN, Gordon CT, Karp BI, McKenna K, Rapoport JL. Smooth pursuit eye movements in childhood onset schizophrenia: quantitative analysis and comparison with ADHD and normal controls. Biological Psychiatry 1996; 40:1144-54. PMID: 8931918
9. Kumra S, **Frazier JA**, Jacobsen LK, McKenna K, Gordon CT, Hamburger S, Smith AK, *Albus KE*, Alaghband-Rad J, Lenane M, Rapoport JL. Childhood-onset schizophrenia: a double blind clozapine trial. Archives of General Psychiatry 1996; 53:1090-7. PMID: 8956674
10. Jacobsen LK, Hommer DW, Hong W, Castellanos FX, **Frazier JA**, Giedd JN, Rapoport JL. Blink rate in childhood-onset schizophrenia: comparison with normal and ADHD controls. Biological Psychiatry 1996; 40:1222-9. PMID: 8959287
11. Jacobsen LK, **Frazier JA**, McKenna K, Gordon CT, Karoum F, Hamburger SD, Molhotra A, Pickar D, Potter WZ, Rapoport JL. Clozapine fluid monoamine metabolites in childhood onset schizophrenia. American Journal of Psychiatry 1996; 154:69-74. PMID: 8988961
12. Kumra S, Jacobsen LK, **Frazier JA,** McKenna K, Gordon CT, Smith AK, Rapoport JL. Clozapine treatment of childhood-onset schizophrenia. Biological Psychiatry. 1996; 39: 530-530.
13. Jacobsen LK, Giedd JN, Rajapakse JC, Hamburger SD, Vaituzis C, **Frazier JA**, Lenane MC, Rapoport JL. Quantitative magnetic resonance imaging of the corpus callosum in childhood onset schizophrenia. Psychiatry Research Neuroimaging 1997; 68:77-86. PMID: 9104755
14. Alaghband-Rad J, Hamburger SD, Giedd J, **Frazier JA**, Rapoport JL. Childhood-onset schizophrenia: biological markers in relation to clinical characteristics. American Journal of Psychiatry 1997; 154:64-8. PMID: 8988960
15. **Frazier JA**, Alaghband-Rad J, Jacobsen L, Lenane MC, Hamburger S, *Albus K,* Smith A, McKenna K, Rapoport JL. Pubertal development and onset of psychosis in childhood onset schizophrenia. Psychiatry Research 1997; 70:1-7. PMID: 9172272
16. Zahn TP, Jacobsen LK, Gordon CT, McKenna K, **Frazier JA**, Rapoport JL. Autonomic nervous system markers of psychopathology in childhood onset schizophrenia. Archives of General Psychiatry, 1997; 54:904-91. PMID: 9337769
17. **Frazier JA**, Spencer T, Wilens T, Wozniak J, Biederman J. Childhood onset schizophrenia, the prototypic psychotic disorder of childhood. In: Dunner DL, Rosenbaum JF (Eds.) Child and Adolescent Psychiatric Clinics of North American: Annual of Drug Therapy; 1997. p. 167-93.
18. Wozniak J, Biederman J, Faraone S, **Frazier J**, Kim J, Millstein R, Gershon J, Thornell A, Cha K, Snyder J. Mania in children with pervasive developmental disorder, revisited. Journal of the American Academy of Child & Adolescent Psychiatry 1997; 36:1552-60. PMID: 9394940
19. Jacobsen LK, Hamburger SD, Van Horn JD, Vaituzis AC, McKenna K, **Frazier JA**, Gordon CT, Lenane MC, Rapoport JL, Zametkin AJ. Cerebral glucose metabolism in childhood onset schizophrenia. Psychiatry Research Neuroimaging 1997; 75:131-44. PMID: 9437771
20. Kumra S., Giedd J., Jacobsen L, McKenna K, **Frazier JA**, Gordon C, Lenane M., Hamburger S, Smith A., Rapoport J. Brain Anatomic Resonance imaging in pediatric patients with psychosis, NOS. Schizophrenia Research 1997; 24: 149-150.
21. Kumra S, Jacobsen LK, Lenane M, Zahn TP, Wiggs E, Alaghband-Rad J, Castellanos FX, **Frazier JA**, McKenna K, Gordon CT, Smith A, Hamburger S, Rapoport JL. Multidimensionally impaired syndrome: is it a variant of very early-onset schizophrenia? Journal of the American Academy of Child & Adolescent Psychiatry 1998; 37:91-9. PMID: 9444905
22. Zahn TP, Jacobsen LK, Gordon CT, McKenna K, **Frazier JA**, Rapoport JL. Attention deficits in childhood- onset schizophrenia: reaction time studies. Journal of Abnormal Psychology 1998; 107:97-108. PMID: 9505042
23. Kumra S, Jacobsen LK, Lenane M, Karp BI, **Frazier JA**, Smith K, Bedwell J, Lee P, Malanga CJ, Hamburger S, Rapoport JL. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. Journal of the American Academy of Child & Adolescent Psychiatry 1998; 37:377-85. PMID: 9549958
24. Wilens T, Biederman J, Spencer T, **Frazier J**, Prince J, Bostic J, Rater M, Soriano J, Hatch M, Sienna M, Millstein R, Abrantes A. A controlled trial of high dose pemoline for adults with ADHD. Journal of Clinical Psychopharmacology 1999; 19:257-64. PMID: 10350032
25. Faraone SV, Biederman J, Weissenbach B, Keith T, Chu MP, Weaver A, Spencer T, Wilens T, **Frazier J**, Sakai J, Cleves M. The dopamine D4 gene 7-repeat allele associated with attention deficit hyperactivity disorder in families ascertained through ADHD adults. American Journal of Psychiatry 1999; 156:768-70. PMID: 10327912
26. **Frazier JA**, *Meyer MC*, Biederman J, Wozniak J, Wilens T, Spencer T, *Kim G,* Shapiro S. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. Journal of the American Academy of Child & Adolescent Psychiatry 1999; 38:960-5. PMID: 10434487
27. Bush G, **Frazier JA**, Rauch SL, Seidman LJ, Whalen PJ, Jenike MA, Rosen BR, Biederman J. Anterior cingulate dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the counting stroop. Biological Psychiatry 1999; 45:1542-52. PMID: 10376114
28. Geller D, Biederman J, Faraone SV, **Frazier J,** Coffey BJ*, Kim G, Bellordre CA*. Clinical correlates of obsessive compulsive disorder in children and adolescents referred to specialized and non-specialized clinical settings. Depression and Anxiety 2000; 11:163-8. PMID: 10945136
29. Geller D, Biederman J, Faraone S, **Frazier JA**, Coffey B, *Kim G, Bellordre C.* Informativeness of structured diagnostic interviews in the identification of Tourette’s Disorder in referred youth. Journal of Nervous & Mental Disease 2000; 188:583-8. PMID: 11009331
30. Coffey B, Biederman J, Geller D, Spencer, T, *Kim G, Bellordre C*, **Frazier J**, Cradock K, Magovcevic M. Distinguishing illness severity from tic severity in children and adolescents with Tourette's Disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2000; 5:562-8. PMID: 10802972
31. Illowsky Karp B, Garvey M, Jacobsen LK, **Frazier JA**, Hamburger SD, Bedwell JS, Rapoport JL. Abnormal neurologic maturation in very early onset schizophrenia. American Journal of Psychiatry 2001; 158:118-22. PMID: 11136643
32. **Frazier, JA,** Biederman, J, Bellordre CA, Garfield SB, Geller DA, Coffey BJ, Faraone SV. Should the diagnosis of Attention Deficit Hyperactivity Disorder be considered in children with pervasive developmental disorder? Journal of Attention Disorders 2001; 4:203-11.

33. **Frazier JA**, Biederman J, Tohen M, Feldman PD, Jacobs, TG, Toma V, Rater M., *Tarazi RA*, *Kim GS*, Garfield SB, *Sohma M*, Gonzalez Heydrich J, Risser RC, Nowlin ZM. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. Journal of Child & Adolescent Psychopharmacology 2001; 11:239-50. PMID: 11642474

34. Geller DA, Biederman J, Faraone SV, *Bellordre CA*, Kim GS, Hagermoser L, *Cradock K*, **Frazier J**, Coffey B. Disentangling chronological age from age of onset in children and adolescents with obsessive-compulsive disorder. International Journal of Neuropsychopharmacology 2001; 4:169-78. PMID: 11466167

35. Geller DA, Biederman J, Faraone SV, *Cradock K*, Hagermoser L, Zaman N, **Frazier JA,** Coffey BJ, Spencer T. Attention deficit/hyperactivity disorder in children and adolescents with obsessive-compulsive disorder: fact or artifact? Journal of the American Academy of Child & Adolescent Psychiatry 2002; 41:52-8. PMID: 11800207

36. **Frazier JA,** Doyle R, *Chiu S,* Coyle J. Treating a Child with Asperger’s Disorder and Comorbid Bipolar Disorder. Invited clinical case conference. American Journal of Psychiatry 2002; 159:13-21. PMID: 11772683

37. Wagner KD, Weller EB, Carlson G, Sachs GA, Biederman J**, Frazier JA**, Wozniak P, Tracy K, Weller RA, Bowden C. An open-label trial of divalproex in children and adolescents with bipolar disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2002; 41:1224-30. PMID: 12364844

38. **Frazier JA,** *Cohen LG,* Jacobsen L, Grothe D, Flood J, Baldessarini RJ, Piscitelli S, *Kim G*, Rapoport JL. Clozapine serum concentrations in children and adolescents with childhood-onset schizophrenia. Journal of Clinical Psychopharmacology 2003; 23:87-91. PMID: 12544379

39. Breeze JL, Hesdorffer DC, Hong X, **Frazier JA**, Renshaw PF. Clinical significance of brain white matter hyperintensities in young adults with psychiatric illness. Harvard Review of Psychiatry 2003; 11:269-83. PMID: 14555427

40. Coffey C, Biederman J, Geller D, **Frazier JA**. Reexamining tic persistence and tic-associated impairment in Tourette’s disorder: findings from a naturalistic follow-up study. Journal of Nervous & Mental Disease 2004;192:776-80. PMID: 15505522

41. De Fossé L, *Hodge SM*, Makris N, Kennedy DN, Caviness VS, McGrath L, Steele S, Ziegler DA, Herbert MR, **Frazier JA**, Tager-Flusberg H, Harris G. Language association cortex asymmetry in autism and specific language impairment. Annals of Neurology 2004; 56:757-66. PMID: 15478219

42. *Ahn M*, **Frazier JA**. Current Updates in Pediatric Bipolar Disorder. Directions in Psychiatry 2004; 24:1-20. 43.*Ahn M,* **Frazier JA**. Diagnostic and Treatment issues in Childhood Onset bipolar disorder. Essential Psychopharmacology 2004; 6:25-44 PMID: 15612652

44. A*hn M*, Sims KB, **Frazier JA**. Risperidone-induced psychosis and depression in a child with a mitochondrial disorder. Journal of Child & Adolescent Psychopharmacology 2005; 15:520-5. PMID: 16092915

45. **Frazier JA**, Carlson, GA. Diagnostically homeless and needing appropriate placement. Journal of Child & Adolescent Psychopharmacology 2005; 15:337-42. PMID: 16092901

46. **Frazier JA**, *Chiu S*, Breeze JL, Makris N, Lange N, Kennedy DK, Herbert MK, *Bent EK, Koneru VK*, Dieterich ME, *Hodge SM*, Rauch SL, Grant PE, Cohen BM, Seidman LJ, Caviness VS, Biederman J. Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. American Journal of Psychiatry 2005; 162:1256-65. PMID: 15994707

47. **Frazier JA**, *Ahn M, DeJong* S, Bent E, Breeze J, *Guiliano A*. Neuroimaging studies in pediatric bipolar disorder: a critical review. Harvard Review of Psychiatry 2005; 13:125-40. PMID: 16020026

48. Hirshberg LM, *Chiu S,* **Frazier JA**. Emerging Brain-Based Interventions for Children and Adolescents: Overview and Clinical Perspective. In Hirshberg L, Chiu S, Frazier JA (Eds). Emerging Brain Based Interventions for Children and Adolescents. Child and Adolescent Psychiatric Clinics of North America January. Philadelphia: WB Saunders; 2005: 14. p 1-19. PMID: 15564050

49. Hirshberg LM, *Chiu S,* **Frazier JA.** Emerging Interventions. Child and Adolescent Psychiatric Clinics of North America Philadelphia: WB Saunders; 2005: 14. p xiii-xvii. PMID: 15564049

50. **Frazier JA**, Breeze JL, Makris N, *Giuliano AS,* Herbert MR, Seidman L, Biederman J, Hodge SM, Dieterich ME, Gerstein E, Kennedy DN, Rauch SL, Cohen B, Caviness VS. Cortical gray matter differences identified by structural magnetic resonance imaging in pediatric bipolar disorder. Bipolar Disorders 2005; 7:555-69. PMID:16403181 PMCID: PMC2072813

51. Doyle RL, **Frazier JA**, Spencer TJ, Geller D, Biederman J, Wilens T. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. Journal of Attention Disorders 2006; 93:543-9. PMID: 16481671

52. Rappaport N, **Frazier JA**, Connor D, Mattison R. From zero to a hundred in a split second: understanding aggression in an eight year old child. Harvard Review of Psychiatry 2006; 14:165-176. PMID: 16787888

53. *Navalta CP, Goldstein J, Ruegg L, Perna D*, **Frazier JA**. Integrating treatment and education for mood disorders: a youth case report. Clinical Child Psychology and Psychiatry 2006; 11:555-568. PMID: 17163224

54. O’Brien LM, Ziegler DA, Deutsch CK, Kennedy DN, Goldstein J, Seidman L, *Hodge SM*, Makris N, Caviness V, **Frazier JA,** Herbert MR. Adjusting for head size differences in volumetric brain studies: a review of common adjustment factors and statistical methods. Harvard Review of Psychiatry 2006; 14: 141-151. PMID: 16787886

55. *Lopez-Larson MP*, **Frazier JA.** Empirical evidence for the use of lithium and anticonvulsants in children with psychiatric disorders. Harvard Review of Psychiatry 2006; 14: 285-304. PMID: 17162653

56. Moore C, **Frazier JA,** Glod CA, Finn C, Breeze J, Dieterich M, Lyoo IK, Renshaw PF. Anterior cingulate cortex glutamate and glutamine levels in children and adolescents with bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2007; 46:524-34. PMID: 17420688

57. Findling RL, **Frazier JA**, Gerbino-Rosen G, Kranzler HN, Kumra S, Kratochvil CJ. “Is there a role for clozapine in the treatment of children and adolescents?” Psychopharmacology Perspectives Column. Journal of the American Academy of Child and Adolescent Psychiatry 2007; 46:423-428. PMID: 17314729

58. McClellan J, Sikich L, Findling RL, **Frazier JA,** Vitiello B, Hlastala SA, Williams E, Ambler D, Hunt-Harrison T, *Maloney AE*, Ritz L, Anderson R, Hamer RM, Koch G, Lieberman JA. The Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS): rationale, design and methods. Journal of the American Academy of Child and Adolescent Psychiatry 2007; 46: 969-978. PMID: 17667476

59. **Frazier JA**, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, *Maloney AE*, Ambler D, Hunt-Harrison T, Hamer RM, Noyes N, Lieberman JA, Sikich L. Treatment of early-onset schizophrenia spectrum disorders: demographic and clinical characteristics. Journal of the American Academy of Child and Adolescent Psychiatry 2007; 46: 979-988. PMID: 17667477

60. *Ahn M,* Breeze JL, Makris N, Kennedy DN, Herbert MR, *Hodge SM*, Seidman LJ, Biederman J, Caviness VS, **Frazier JA**. Anatomic brain magnetic resonance imaging (MRI) study of basal ganglia in pediatric bipolar disorder. Journal of Affective Disorders 2007; 104: 147-154. PMID: 16020026

61. **Frazier JA,** Breeze JL, Papadimitriou G, Kennedy DN, *Hodge SM*, Moore CM, Howard JD, Rohan MP, Caviness V, Makris N. White matter abnormalities in children with and at risk for bipolar disorder. Bipolar Disorders 2007; 9: 799-809. PMID: 18076529

62. **Frazier JA**, *Hodge S*, Breeze J, Giuliano A, *Terry J,* Kennedy D, *Lopez-Larson M,* Caviness V, Seidman L, Zablotsky B, Makris N. Diagnostic and Sex Effects on Limbic Volumes in Early-Onset Bipolar Disorder and Schizophrenia. Schizophrenia Bulletin 2008; 34: 37-46. PMID: 18003631 PMCID: PMC2632388

63. **Frazier JA**. Child Psychiatry: Addressing Emerging Clinical Challenges. Introduction. Harvard Review of Psychiatry 2008; 16: 67-68. PMID: 18415879

64. Sikich L, **Frazier JA**, McClellan J, Findling R, Vitiello B, Ritz L, Ambler D, Puglia M, *Maloney AE*, *Michael E, DeJong S, Slifka K, Noyes N*, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Double-blind Comparison of Antipsychotics in Early Onset Schizophrenia and Schizoaffective Disorder. American Journal of Psychiatry 2008;165:1420-31. PMID: 18794207

65. *Shin L, Bregman H*, **Frazier JA,** Noyes N**.** An Overview of Obesity in Children with Psychiatric Disorder Taking Atypical Antipsychotics. Harvard Review of Psychiatry 2008; 16: 69-79. PMID: 18415880

66. Findling, RL **Frazier JA,** Kafantaris V, Kowatch R, McClellan J, Pavuluri M, Sikich LM, Hlastala S, Hooper SR, Demeter CA, Bedoya D, Brownstein B, Taylor-Zapata P. The Collaborative Lithium Trials (CoLT): Specific Aims, Methods, and Implementation. J Child Adolesc Psychiatry and Mental Health 2008; 12: 21. PMID:18700004 PMCID: PMC2531078

67. Soares JC, **Frazier JA**. Neurobiology of pediatric mood disorders: are we there yet? J Child Adolesc Psychopharmacology 2008; 18: 549. PMID: 19108658

68. **Frazier JA,** Soares JC. Neurobiology of pediatric mood disorders: Part II. J Child Adolesc

Psychopharmacology 2009; 19:1-2. PMID: 19232017

69. *Lopez-Larson M*, *Michaels E,* Moore C, *Terry J*, Breeze JL, Kennedy DN, Makris N, *Hodge SM*, Caviness VS, **Frazier JA.** Subcortical volumes: Differences between youths with bipolar disorder and comorbid attention- deficit/hyperactivity disorder compared to youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacology 2009; 19:31-9. PMID: 19232021 PMCID: PMC2993054

70. Kryzhanovskaya L, Schulz C, McDougle CJ, **Frazier JA**, Dittman R, Robertson-Plouch C, Bauer BS, Xu W, Wang WV, Carlson J, Tohen M. The Efficacy and Safety of Olanzapine in Adolescents with Schizophrenia: The Results from a Double-blind, Placebo-Controlled Trial. J Acad Child Adolesc Psychiatry 2009; 48: 60-70. PMID: 19057413

71. Carlson G, Findling R, Post R, Birmaher B, Blumberg H, DelBello M, Fristad M, **Frazier J,** Hammen C, Hinshaw S, Kowatch R, Leibenluft E, Meyer S, Pavuluri M, Wager K, Tohen M. AACAP 2006 Research Forum: Advancing research in early onset bipolar disorder: barriers and suggestions. Journal of Child and Adolescent Psychopharmacology 2009; 19:3-12. PMID: 19232018

72. *Shin L, Bregman H,* Breeze J, *Noyes N*, **Frazier JA.** Metformin for Weight Control in Pediatric Patients on Atypical Antipsychotic Medications. Journal of Child and Adolescent Psychopharmacology 2009; 19:275-9. PMID: 19519262

73. Essock SM, Covell NH, Leckman-Westin E, Lieberman J, Sederer L, Kealey E, Finnerty M, and Members of the Scientific Advisory Committee and Psychopharmacology work group. Identifying Clinically Questionable Psychotropic Prescribing Practices and Their Prevalence Among Medicaid Recipients in New York State. Psychiatric Services 2009; 60:1595-602. PMID: 19952148

*Members of the Scientific Advisory Committee who participated in the preparation of this manuscript include the following:* Bartels SJ, Buchanan RW, Buckley PF, Calabrese JR, Conley RR, Dixon L, Emslie GJ, Findling RL, **Frazier JA,** Goff DC, Greenhill L, Jeste DV, Kane JM, Marder SR, Meyers BS, Miller AL, Nierenberg AA, Olfson M, Roose SP, Schneider LS, Schooler NR, M. Shear MK, Stein B, Stroup TS, Thase ME, Wagner KD, Wisner KL. Additional members of the Scientific Advisory at the original meeting include the following: Deegan PE, Drake RE, Hoagwood K.

74. Hooper SR, *Giuliano A,* Youngstrom E, Brieger D, Sikich L**, Frazier JA**, Findling R, McClellan J, Hamer R, Vitiello B, Lieberman JA. Neurocognition in Early Onset Schizophrenia Spectrum Disorders: Schizophrenia versus Schizoaffective Disorder. J Am Acad Child Adolesc Psychiatry 2010; 49:52-60. PMID: 20215926

75. Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB, Miller KJ, **Frazier JA,** Silverstein I, Picker J, Weissman L, Raffalli P, Jeste S, Demmer LA, Peters HK, Brewster SJ, Kowalczyk SJ, Rosen- Sheidley B, McGowan C, Duda AW, Lincoln SA, Lowe KR, Schonwald A, Robbins M, Hisama F, Wolff R, Becker R, Nasir R, Urion DK, Milunsky JM, Rappaport L, Gusella JF, Walsh CA, Wu BL, and Miller DT on behalf of the Autism Consortium Clinical Genetics/DNA Diagnostics Collaboration Clinical Genetic Testing for Patients with Autism Spectrum Disorders. Pediatrics 2010, 125:727-35. PMID: 20231187; PMCID: PMC4247857

76. *Hodge SM,* Makris N, Kennedy DN, Caviness VS, Howard J, McGrath L, Steele S, **Frazier JA**, Tager-Flusberg H, Harris GJ. Cerebellum, Language, and Cognition in Autism and Specific Language Impairment. J Autism Dev Disorder 2010; 40:300-316. PMID: 19924522 PMC3771698

77. Findling RL, Johnson JL, McClellan J, **Frazier JA,** Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, *Maloney AE*, *Kaufman Em, Noyes N*, Sikich L. Double-blind maintenance safety and effectiveness finding from the Treatment of Early-Onset Schizophrenia Spectrum Study (TEOSS). J Am Acad Child Adoles Psychiatry 2010; 49:583-594. PMID: 20494268 PMCID: PMC2882800

78. Zhang N, Rane P, Huang W, Liang Z, Kennedy D, **Frazier JA**, King J. Mapping resting-state brain networks in conscious animals. J Neurosci Methods 2010; 189:186-96. PMID: 20382183 PMCID: PMC2896018

79. Findling RL, Landersdorfer CB, Pavuluri M, McNamara NK, McClellan J**, Frazier JA**, Sikich L, Kowatch R, Lingler J, Faber J, Taylor-Zapata P, Jusko WJ. First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents. J Clin Psychopharm 2010; 4:404-10. PMID: 20531219 PMCID: PMC2967308

80. *Lopez-Larson M*, Breeze JL, Kennedy, DN, *Hodge SM*, Tang L, Moore C, Giuliano AJ, Makris N, Caviness VS, **Frazier JA**. Age-Related Changes in the Corpus Callosum in Early-Onset Bipolar Disorder Assessed Using volumetric and Cross-Sectional Measurements. Brain Imaging and Behavior 2010; 4:220-31. PMID: 20686873 PMCID: PMC3711475

81. Gönenç A**, Frazier JA**, Crowley DJ, Moore CM. Combined Diffusion Tensor Imaging and T2 Relaxometry in Early Onset Bipolar Disorder. The Journal of the American Academy of Child and Adolescent Psychiatry 2010;49:1260-1268. PMID: 21093775 PMC4021485

82. Findling RL, Kafantaris V, Pavuluri M, McNamara NK; McClellan J, **Frazier JA;** Sikich L, Kowatch R; Lingler J; Faber J, Rowles BM, Clemons TE; Taylor-Zapata P. Dosing Strategies for lithium monotherapy in children and adolescents with bipolar I disorder. The Journal of Child and Adolescent Psychopharmacology 2011; 21:195-205. PMID: 21663422 PMCID: PMC3111866

83. *Dvir Y*, **Frazier JA.** Autism and Schizophrenia. Psychiatric Times 2011; 28.

84. **Frazier JA**. Review: Limited evidence for use of second-generation antipsychotics in anxiety disorders. Evidence Based Mental Health 2011; 14(3):76. PMID: 21764875

85. O’Brien LM, Ziegler DA, Deutsch CK, **Frazier JA**, Herbert MR, Locascio JJ. Statistical adjustments for brain size in volumetric neuroimaging studies: Some practical implications in methods. Psychiatric Research 2011;193(2):113-22. PMID: 21684724; PMCID: PMC3520982

86. *Nwosu BU*, Meltzer B, Maranda L, Ciccarelli C, Reynolds D, Curtis L, King J, **Frazier JA,** Lee MM. A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second- generation antipsychotics. Journal of Pediatric Endocrinology and Metabolism 2011; 24:619-626. PMID: 22145446

87. Kennedy DN, *Hodge SM*, Yong G, **Frazier JA**, Haselgrove C. The Internet Brain Volume Database: A Public Resource for Storage and Retrieval of Volumetric Data. Neuroinformatics 2012; 10:129-40. PMID: 21931990 PMCID: PMC3417226

88. Kennedy DN, Haselgrove C, *Hodge SM*, Pallavi S, Makris N, **Frazier JA**. CANDIShare: A Resource for Pediatric Neuroimaging Data, Neuroinformatics 2012; 10: 319-22. PMID: 22006352 PMCID: PMC3417225

89. **Frazier JA**, Giuliano A, Johnson JL, *Yakuitis L*, Youngstrom EA, Breiger D, Sikich L, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA, Hooper SR. Neurocognitive Outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders. Study Journal of the American Academy of Child and Adolescent Psychiatry 2012; 51: 496-505. PMID: 22525956 PMCID: PMC3337647

90. Chen Y, Norton DH, McBain R, Gold J, **Frazier JA**, Coyle JT. Enhanced local processing of dynamic visual information in autism: Evidence from speed discrimination. Neuropsychologia 2012; 50:733-9. PMID:22261399; PMCID: PMC4094132

91. Brown TT, Kuperman JM, Chung Y, Erhart M, McCabe C, Hagler DJ Jr, Venkatraman VK, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, **Frazier JA**, Gruen JR, Kaufmann WE, Kenet T, Kennedy DN, Murray SS, Sowell ER, Jernigan TL, Dale AM. Neuroanatomical Assessment of Biological Maturity. Curr Biol, 2012; 22: 1693-8. PMID: 22902750 PMCID: PMC3461087

92. *Maloney AE, Yakutis LJ*, **Frazier JA.** Empirical evidence for psychopharmacologic treatment in early-onset psychosis and schizophrenia. Child Adolesc Psychiatry Clin N Am. 2012; 21:885-909. PMID: 23040906

93. Fjell AM, Walhovd KB, Brown TT, Kuperman JM, Chung Y, Hagler DJ, Venkatraman V, Roddey JC Erhart M, McCabe C, Akshoomoff N, Amaral DG, Bloss CS, Libiger O, Darst BF, Schork NJ, Casey BJ, Chang L, Ernst TM, Gruen JR, Kaufman WE, Kenet T, **Frazier J,** Murray SS, Sowell EF, van Zijl P, Mostofsky S, Jernigan TL, Dale AM. Multi Modal Imaging of the Self-Regulation Developing Brain. PNAS, 2012; 109: 19620-19625. PMID: 23150548; PMCID: PMC3511748

94. Walhovd KB, Fjell AM, Brown TT, Kuperman JM, Chung Y, Hagler DJ Jr, Roddey JC, Erhart M, McCabe C, Akshoomoff N, Amaral DG, Bloss CS, Libiger O, Schork NJ, Darst BF, Casey BJ, Chang L, Ernst TM, **Frazier J**, Gruen JR, Kaufmann WE, Murray SS, van Zijl P, Mostofsky S, Dale AM; for the Pediatric Imaging, Neurocognition, and Genetics Study. Long-term influence of normal variation in neonatal characteristics on human brain development. Proc Natl Acad Sci 2012; 109:20089-20094. PMID: 23169628; PMCID: PMC3523836

95. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM; Alzheimer's Disease Neuroimaging Initiative; Pediatric Imaging, Neurocognition, and Genetics Study, Weiner M, Aisen P, Petersen R, Jack CR Jr, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP,Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff- Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Ging-Yuek, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E, Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y, Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B, Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, **Frazier J**, Kennedy D, Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H. Proc Natl Acad Sci U S A. 2012 ;109:3985-90 PMID: 22343285 PMCID: PMC3309762

96. *Sikoglu ME*, Jensen JE, Vitaliano G, Renshaw PF, **Frazier JA,** Moore CM. Bioenergetic Measurements in Children with Bipolar Disorder: A Pilot 31P Magnetic Resonance Spectroscopy Study. PLoS One, 2013;8(1):e54536. doi: 10.1372012 PMID: 23382910 PMCID: PMC3559786

97. Findling RL, Kafantaris V, Pavuluri M, McNamara NK, **Frazier JA**, Sikich L, Kowatch R, Rowles BM, Clemons TE, Taylor-Zapata P. Post-acute effectiveness of lithium in pediatric bipolar I disorder. J Child Adolesc Psychopharmacology. 2013; 23:80-90. PMID: 23510444 PMCID: PMC3609605

98. Czerniak SM, *Sikoglu ME,* King JA, DN, Mick E, **Frazier JA,** Moore CM. Areas of the Brain Modulated by Single-Dose Methylphenidate Treatment in ADHD Patients During Task- Based fMRI: A Systematic Review. Harvard Review of Psychiatry, 2013 May-Jun;21:151-62. PMID: 23660970

99. *Dvir Y,* **Frazier JA**. Psychotic disorders in youth: diagnostic and treatment challenges. Child Adoles Psychiatry Clin N Am. 2013; 22;xiii-xiv PMID: 24012085

100. *Dvir Y, Denietolis B,* **Frazier JA.** Childhood trauma and psychosis. Child Adolesc

Psychiatry Clin N Am. 2013 Oct;22(4):629-41. PMID: 24012077

101. *Cochran DM, Dvir Y*, **Frazier JA**. "Autism-plus" Spectrum Disorders: Intersection with Psychosis and the Schizophrenia Spectrum. Child Adolesc Psychiatry Clin N Am. 2013 Oct;22:609-27. PMID: 24012076

102. *Cochran DM, Fallon D, Hill M*, **Frazier JA**. The role of oxytocin in psychiatric disorders: A review of biological and therapeutic research findings. Harvard Review of Psychiatry. 2013; 21: 219-47. PMID: 24651556; PMCID: PMC4120070

103. Eicher JD, Powers NR, Miller LL, Akshoomoff N, Amaral DG, Bloss CS, Libiger O, Schork NJ, Darst BF, Casey BJ, Chang L, Ernst T, **Frazier J**, Kaufmann WE, Keating B, Kenet T, Kennedy D, Mostofsky S, Murray SS, Sowell ER, Bartsch H, Kuperman JM, Brown TT, Hagler DJ Jr, Dale AM, Jernigan TL, St Pourcain B, Davey Smith G, Ring SM, Gruen JR; Pediatric Imaging, Neurocognition, and Genetics Study. Genome-wide association study of shared components of reading disability and language impairment. Genes Brain Behav. 2013 Nov;12:792-801. PMID: 24024963 PMCID: PMC3904347

104. Akshoomoff N, Newman E, Thompson WK, McCabe C, Bloss CS, Chang L, Amaral DG, Casey BJ, Ernst TM, **Frazier JA,** Gruen JR Kaufmann WE, Kenet T, Kennedy DN, Libiger O, Mostofsky S, Murray SS, Sowel EF, Schork N, Dale AM, Jernigan TL. The NIH Toolbox Cognition Battery: Results From a Large Normative Developmental Sample. Neuropsychology 2014;1: 1-10. PMID24219608; PMCID: PMC3925365

105. Mick E, McGough J, Deutsch CK, **Frazier JA**, Kennedy D, Golberg RJ. Genome wide association study of proneness to anger. PLoS One. 2014 9 (1): e87257doi10.137/journal.pone.0087257.eCollection 2014. PMID: 24489884; PMCID: PMC3905014

106. *Dvir Y,* Ford JD, *Hill M*, **Frazier JA**. Childhood maltreatment, Emotional dysregulation, and psychiatric comorbidities. Harvard Review of Psychiatry. 2014; 22: 149-61. PMID: 24704784; PMCID: PMC4091823

107. R*ane P,* Haselgrove C, Hodge SM, **Frazier JA,** Kennedy DN. Structure-centered portal for child psychiatry research. Front Neuroinform. 2014;8:47. PMID: 24817850 PMC4012203

108. *Maloney A*, Mick EO, **Frazier JA**. Aripiprazole Decreases Irritability in 12 out of 14 Youth with Autism Spectrum Disorders. Journal of Child and Adolescent Psychopharmacology. 2014; 24: 357-9. PMID: 2428130; PMCID:PMC4137505

109. Woodberry KA, Serur RA, Hallinan SB, Mesholam-Gately RI, Giuliano AJ, Wojcik JD, Keshavan, MS, **Frazier** **JA**, Goldstein JM, Shenton ME, McCarley RW, Seidman LJ.. Frequency and pattern of childhood symptom onset reported by first episode schizophrenia and clinical high risk youth. Schizophrenia Research. 2014;158: 45-51. PMID 24924404; PMCID: PMC4207713

110. Noble KG, Houston SM, Natalie H Brito NH, Bartsch H**,** Kane E**,** Kuperman JM, Akshoomoff N, Amaral DG, Bloss CS, Libiger O, Schork NJ, Murray SS, Casey BJ, Chang L, Ernst TM, **Frazier** JA**,** Gruen JR, Kennedy DN, Van Zijl P, Mostofsky S**,** Kaufmann WE, Kenet T, Dale AM, Jernigan TL, Sowell ER. Family Income, Parental Education and Brain Structure in Children and Adolescents. Nature Neuroscience. 2015;18:773-8. PMID: 25828052; PMCID: PMC4414816.

111. R*ane P, Cochran D, Hodge S*, Haselgrove C, Kennedy DN, **Frazier JA.** Connectivity in Autism: A review of MRI connectivity studies. Harvard Review of Psychiatry. 2015; 23: 223-44. PMID: 26146755.

112. *Cochran DM, Sikoglu EM, Hodge SM*, Edden RAE, Foley A, Kennedy DN, Moore CM, & **Frazier JA.** Relationship between glutamine, gamma-aminobutyric acid and social cognition in autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 2015; 25: 314-22. PMID: 25919578; PMCID: PMC4442578.

113. *Sikoglu EM\*, Liso Navarro* *AA*\*, Starr D, *Dvir Y*, Nwosu BU, Czerniak SM, Rogan RC, Castro MC, Edden RAE, **Frazier JA**, Moore CM. VitaminD3 Supplemental Treatment for Mania in Youth with Bipolar Spectrum Disorders. Journal of Child and Adolescent Psychopharmacology. 2015;25:415-24. PMID: 26091195. PMCID: PMC4491165.

114. **Frazier JA,** *Wood ME*, Ware J, Joseph R, Kuban KC, O’Shea M, Allred EN, Leviton A. Antecedents of the Child Behavior Checklist-Dysregulation Profile in Children Born Extremely Preterm. Journal of the American Academy of Child and Adolescent Psychiatry. 2015; 54: 816-23. PMID: 26407491. PMCID: PMC4615708.

115. Byron G, Ziedonis DM, McGrath C, **Frazier JA,** deTorrijos F, Fulwiler C. Implementation of Mindfulness Training for Mental Health Staff: Organizational Context and Stakeholder Perspectives. Mindfulness. 2015; 6:861-871*.* PMID: 26500708. PMCID: PMC4612531

116. Newman E, Thompson WK, Bartsch H, Hagler DJ, Chen CH, Brown TT, Kuperman JM, McCabe C, Chung Y, Libiger O, Akshoomoff N, Bloss CS, Casey BJ, Chang L, Ernst TM, **Frazier JA**, Gruen JR, Kennedy DN, Murray SS, Sowell ER, Schork N, Kenet T, Kaufmann WE, Mostofsky S, Amaral DG, Dale AM, Jernigan TL. Anxiety is related to indices of cortical maturation in typically developing children and adolescents. Brain Structure and Function. 2016; 221:3013-25. PMID:26183468. PMCID: PMC5064818.

117. Findling RL, Robb A, McNamara NK, Pavuluri MN, Kafantaris V, Scheffer R, **Frazier JA**, Rynn M, Delbello M, Kowatch RA, Rowles BM, Lingler J, Martz, Anand R, Clemons TE, Taylor-Zapata P. Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. Pediatrics, 2015;136:885-94. PMID: 26459650. PMCID: PMC4621794.

118.*Wood M*, **Frazier JA**, Lapane K, Nordeng H. Prenatal triptan exposure and early childhood

neurodevelopmental outcomes: an application of propensity score calibration to adjust for

unmeasured confounding by migraine severity Pharmacoepidemiology and Drug Safety. 2016;

25:493-502; PMID: 26554750.

119. Eicher JD, Montgomery AM, Akshoomoff N, Amaral DG, Bloss CS, Libiger O, Schork NJ, Darst BF, Casey BJ, Chang L, Ernst T, **Frazier JA**, Kaufmann WE, Keting B, Kenet T, Kennedy D, Mostofsky S, Murray SS, Wowell ER, Bartsch J, Kuperman JM, Brown TT, Hagler DJ, Dale AM, Jernigan TL, Gruen JR. Dyslexia and language impairment associated with genetic markers influence cortical thickness and white matter in typically developing children. Brain Imaging and Behavior. 2016; 10: 272-82 PMID: 26414677. PMCID: PMC4639472

120. Jernigan TL, Brown TT, Hagler DJ, Akshoomoff N, Bartsch H, Newman E, Thompson WK, Bloss CS, Murray SS, Schork N, Kennedy DN, Kuperman JM, McCabe C, Chung Y, Libiger O, Maddox M, Casey BJ, Chang L, Ernst TM, **Frazier JA**, Bruen JR, Sowell ER, Kenet T, Kaufmann WE, Mostofsky S, Amaral DG, Dale AM. The Pediatric Imaging, Neurocognition and Genetics (PING) Data Repository. Neuroimage, 2016; 124:1149-1154. PMID: 25937488. PMCID: PMC25937488.

121. *Wood M*, Lapane K, **Frazier JA,** YstromE**,** Nordeng H. Prenatal triptan exposure and internalizing and externalizing behavior problems in three year old children: results from the Norwegian Mother and Child Cohort Study. Paediatric and Perinatal Epidemiology. 2016;30:190-200. PMID 26525300*.* PMCID: PMC474940:5.

122. Kuban KCK, Joseph RM, O’Shea TM, Allred EN, Heeren T, Douglass L, Stafstrom CE, Jara H, **Frazier JA**, Hirtz D, Leviton A, for the ELGAN Study Investigators. Girls and boys born before 28 weeks gestation: risks of cognitive, behavioral, and neurological outcomes at age 10 years.  J Pediatric. 2016; 173: 69-75. PMID: 27004675 PMCID: PMC4884461

123. Chang L, Douet V, Bloss CS, Lee K, Pritchett A, Jernigan TL, Akshoomof N, Murray SS**, Frazier J**, Kennedy DK, Amaral, DG, Gruen J, Kaufmann WE, Casey BJ, Sowell E, Ernst T. Gray Matter Maturation and Cognition in Children with Different APOE- epsilon Genotypes. Neurology. Neurology. 2016 Aug 9;87(6):585-94. doi: 10.1212/WNL.0000000000002939.PMID: 27412137

124. Kim SH, Joseph RM, **Frazier JA**, O’Shea TM, Chawarska K, Allred EN, Leviton A, Kuban KK. Predictive Validity of the Modified Checklist for Autism in Toddlers (M-CHAT) Born Very Preterm. Journal of Pediatrics. Journal of Pediatrics. 2016; 178:101-107. PMID: 27592094.

125. Landersdorfer CB, Findling RL, **Frazier JA**, Kafantaris V, Kirkpatrick. Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regmines via Population Pharmacokinetics/Pharmacodynamics. Clinical Pharmacokinetics. 2016. Jul 8 [Epub ahead of print]. PMID: 27393139.

126. *Honor LB*, Haselgrove C, **Frazier JA**, Kennedy DN. Data Citation in Neuroimaging: Proposed Best Practices for Data Identification and Attribution. Frontiers in Neuroinformatics. Front Neuroinform. 2016 Aug 12;10:34. doi: 10.3389/fninf.2016.00034. Erratum in: [Front Neuroinform. 2016 Oct 05;10 :43](https://www.ncbi.nlm.nih.gov/pubmed/27708574). PMID: 27570508. PMCID: PMC4981598

127. Fitzpatrick P, **Frazier JA**, *Mitchell T, Cochran D*, Coleman C, Schmidt RC.Impairments of Social Motor Synchrony Evident in Autism Spectrum Disorder. Frontiers in Psychology. 2016 Aug 31;7:1323. doi: 10.3389/fpsyg.2016.01323. PMID: 27630599. PMCID: PMC5005316.

128. Kuban KCK, Joseph RM, O’Shea TM, Heeren, T, Fichorova RN, Douglass L, Jara H, **Frazier JA**, Hirtz D, RollinsJV, Paneth N, for the ELGAN Study Investigators..Circulating inflammatory-associated proteins in the First Month of Life and Cognitive Impairment at age 10 years in Children Born Extremely Preterm. The Journal of Pediatrics. 2016 Oct 24. pii: S0022-3476(16)31038-1. doi: 10.1016/j.jpeds.2016.09.054. [Epub ahead of print] PMID: 27788929.

129. *Wood ME*, **Frazier JA,** Nordeng HM, Lapane KL. [Longitudinal changes in neurodevelopmental](https://www.ncbi.nlm.nih.gov/pubmed/27625061)

[outcomes between 18 and 36 months in children with prenatal triptan exposure: findings from the Norwegian Mother and Child Cohort Study.](https://www.ncbi.nlm.nih.gov/pubmed/27625061) BMJ Open. 2016 Sep 13;6(9):e011971. doi: 10.1136/bmjopen-2016-011971. PMID:27625061. PMCID: PMC5030558.

130*. Honor LB*, Haselgrove C, **Frazier JA,** Kennedy DN. Corrigendum: Data Citation in Neuroimaging: Proposed Best Practices for Data Identification and Attribution. Front Neuroinform. 2016. Oct 5:10:43. PMID: 27708574. PMCID: PMC5050202.

131. Kuban KC, Joseph RM, O’Shea TM, Heeren T, Richorova RN, Douglass L, Jara H, **Frazier JA,** Hirtz D, Rollins JV, Paneth N; ELGAN study Investigators. Circulating Inflammatory-Associated Proteins in the First Month of Life and Cognitive Impairment at Age 10 Years in Children Born Extremely Preterm. Journal of Pediatrics. 2016; Oct 24. pii: S0022-3476(16)31038-1. doi: 10.1016/j.jpeds.2016.09.054. [Epub ahead of print]. PMID:27788929

132. Joseph RM. Korzeniewski SJ, Allred EN, O'Shea TM, Heeren T, **Frazier JA**, Ware J, Hirtz D,Leviton A, Kuban K; ELGAN Study Investigators. [Extremely low gestational age and very low birthweight for gestational age are risk factors for autism spectrum disorder in a large cohort study of 10-year-old children born at 23-27 weeks' gestation](https://www.ncbi.nlm.nih.gov/pubmed/27847193). Am J Obstet Gynecol. 2016 Nov 12. pii: S0002-9378(16)31989-5. doi: 10.1016/j.ajog.2016.11.1009. [Epub ahead of print], PMID: 27847193

*Italics= individuals mentored by Dr. Frazier*

***Educationally Relevant Publications-Invited Chapters***

1. Coffey B, **Frazier JA**, Chen S. Comorbidity, Tourette Syndrome and Anxiety Disorders. In: Advances in Neurology. New York: Raven Press; 1992. p. 96-104.

2. **Frazier JA**, Barrett R, Walters A, Feinstein C. Moderate to profound mental retardation. In: Noshpitz J and Alessi NE (Eds.) Handbook of child & adolescent psychiatry. New York: Wiley and Sons; 1997. p. 397-408.

3. **Frazier JA**, Spencer T, Wilens T, Wozniak J, Biederman J. Childhood onset schizophrenia, the prototypic psychotic disorder of childhood. In: Dunner DL, Rosenbaum JF (Eds.) Child and Adolescent Psychiatric Clinics of North American: Annual of Drug Therapy; 1997. p. 167-93.

4. Wilens T, Spencer TJ, **Frazier JA**, Beiderman J. Child and adolescent psychopharmacology. In: Ollendick T, Hersen M, (Eds.) Handbook of child psychopathology, 3rd ed. New York; Plenum Press, 1998: 603-36.

5. **Frazier JA**. Mental retardation. In: Finberg L, Ed. Saunders manual of pediatric practice. Philadelphia: W.B. Saunders Company; 1998. p. 154-6.

6. **Frazier JA**. Autism, Asperger’s and Schizophrenia. In: Finberg L. (Ed.) Saunders manual of pediatric practice. Philadelphia: W.B. Saunders Company; 1998. p. 172-4.

7. **Frazier JA**. The mentally retarded person. In: Nicoli A, Ed. The New Harvard Guide to Psychiatry.

Cambridge: The Belkap Press, 1999: 660-71.

8. *Abrams A*, **Frazier JA**. Psychopharmacology in children and adolescents. In: Stern T. (Ed.) The MGH board review text, New York: McGraw-Hill; 2000. p. 31-40.

9. *Chiu S,* **Frazier JA**. Autism, Asperger’s and Schizophrenia. In: Finberg L and Kleinman RE. (Eds.) Saunders manual of pediatric practice. Philadelphia: WB Saunders Company, 2002; 191-5.

10. *Chiu S*, **Frazier JA**. Mental retardation. In: Finberg L and Kleinman RE. Eds. Saunders manual of pediatric practice. Philadelphia: WB Saunders Company; 2002. p. 188-91.

11. **Frazier JA.** Agitation and Aggression. In: Martin A, Scahill L, Charney D, Leckman J (Eds), Pediatric

Psychopharmacology: Principles and Practice. New York: Oxford University Press; 2003. p. 671-85.

12. *DeJong S*, **Frazier JA.** Bipolar disorder in children with pervasive developmental disorders. In: Geller B, DelBello M. (Eds). Child and early adolescent bipolar disorder. New York: Guilford Publications; 2003. p. 51- 75.

13. *Abrams A* and **Frazier JA**. Psychopharmacology in children and adolescents. In Stern TA, Herman JB (Eds) Psychiatry Update and Board Preparation, Second Edition. New York: MaGraw Hill; 2004. p.33-42.

14. *DeJong S, Giuliano AJ*, **Frazier, JA.** Antipsychotic Medications in Child Psychiatry, In Chang K, Steiner H (Eds). Handbook of Mental Health Interventions in Children and Adolescents: An Integrated Developmental Approach. New York: Jossey-Bass/Wiley; 2004. p. 413-64.

15. **Frazier JA***, Bregman H, Jackson JA*. Atypical Antipsychotics in the Treatment of Early Onset Bipolar Disorder, In Geller B, Delbello M (Eds) Treating Child and Adolescent Bipolar Disorder. New York: Guilford Press; 2008. P69-108.

16. *Terry J, Lopez-Larson M*, **Frazier JA.** Magnetic Resonance Imaging Studies in Early Onset Bipolar Disorder: An Updated Review. In Dickstein D and Hunt J (eds). Child and Adolescent Psychiatric Clinics of North America. Philadelphia: WB Saunders 2009; 19:421-39.

17. *Meltzer B, Castro M*, **Frazier JA.** Aggression. In Martin A. Scahill L, Kratochvil C. (Eds) Pediatric Psychopharmacology: Principles and Practice-Second Edition. New York: Oxford University Press 2010;671-681

18. *Dvir Y,* Madaan V, *Yakutis, L***, Frazier JA**, Wilson DR. Autism Spectrum Disorders and Schizophrenia, In Ritsner MS (ed). Textbook of Schizophrenia Spectrum Disorders, Volume I: Theoretical Issues, and Neurobiology Research. New York, NY: Springer, 2011; 143-162.

19. *Ahn, M.*, Yakutis, L., **Frazier, JA.** Use of Antidepressant Medications in Children and Adolescents. In Rothschild, A. (Ed), *The Evidence-Based Guide to Antidepressant Medications.* Arlington, VA: American Psychiatric Publishing, Inc. Arlington, VA: APA, 2012; 189-226.

20. Bethea TG, Bertelli MO, Blumberg ER, Charlot LR, **Frazier JA**, Standfield AC. Autism Spectrum Disorder. In Fletcher RJ, Barnhill J, Cooper SA (Ed). Diagnostic Manual-Intellectual Disability. A Textbook of Diagnosis of Mental Disorders in Persons with Intellectual Disability. (DM-ID 2). Kingston, NY:NADD Press. 2016;115-138

21. *Skehan B, Dvir D.*, **Frazier JA.** Schizophrenia in children and adolescents. In Brent D.(Ed) *UpTodate.* Under review

22. *Denietolis BM* and **Frazier JA.** Early Onset Schizophrenia. In Ingber E(Ed), *The SAGE Encyclopedia of Intellectual and Developmental Disorders.* Under review.

23. *Denietolis BM* and **Frazier JA.** Adult Onset Schizophrenia. In Ingber E(Ed), *The SAGE Encyclopedia of Intellectual and Developmental Disorders*. Under review.

***Special Journal Volumes for which served as Editor***

1. Hirshberg L, *Chiu S,* **Frazier JA**. (Coeditors) Emerging Interventions. Child and Adolescent Psychiatric Clinics of North America. Philadelphia: WB Saunders. January 2005. 14.

2. **Frazier JA,** Carlson G. (Coeditors). Psychosis, NOS. Special Volume of Journal of Child and Adolescent Psychopharmacology. New Rochelle, NY: Mary Ann Liebert, Inc. publishers. 2005: 6.

3. **Frazier JA** (Editor) Child Psychiatry: Addressing Emerging Clinical Challenges. Harvard Review of

Psychiatry. New York, NY: Informa Healthcare. 2008: 2.

4. Soares J, **Frazier JA.** (Coeditors). The Neurobiology of Pediatric Mood Disorders (Part I). Special Volume of Journal of Child and Adolescent Psychopharmacology. New Rochelle NY: Mary Ann Liebert, Inc. publishers. 2008: 18 (6).

5. **Frazier JA,** Soares J. (Coeditors). The Neurobiology of pediatric mood disorders (Part II). Journal of Child and Adolescent Psychopharmacology. New Rochelle Mary Ann Liebert, Inc. publishers 2009; 19 (1).

6. *Dvir Y* and **Frazier JA** (Co-Editors). Child and Adolescent Clinics of North America. Special Volume on Psychosis. Child Adolesc Psychiatry Clinics N Am. 2013 Oct;22(4)

7. **Frazier JA** and McDougle (Co-Editors). Harvard Review of Psychiatry. Special Volume on Autism. 2014 Mar- Apr22 (2)

***Conference Proceedings (only containing data not published in peer reviewed journals)***

1. Rapoport JL, Schulz S. Why study teenagers with psychosis? Study Group. Presenter**: JA Frazier.** American College of Neuropsychopharmacology 33rd Annual Meeting Scientific Abstracts.-Puerto Rico. 1994; page 37.

2. Lieberman JA, Bilder RM, Benes F, Bogerts B, Buchsbaum M, Giedd JG Krishnan KRR, Rapoport JL. Striatal pathology in schizophrenia developmental, disease or treatment effect? Study Group. Presenter: **JA Frazier.** American College of Neuropsychopharmacology 33rd Annual Meeting Scientific Abstracts-Puerto Rico. 1994; page 3.

3. **Frazier JA.** DSM-IV versus child manual? Childhood Schizophrenia. Symposium. Scientific Proceedings of the American Academy of Child and Adolescent Psychiatry. 1994.

4. **Frazier JA.** Special Topics in Psychopharmacology: Pharmacological treatment of childhood schizophrenia. Institute. Scientific Proceedings of the American Academy of Child and Adolescent Psychiatry Annual Meeting. 1995.

5. **Frazier JA.** Childhood onset schizophrenia, pervasive developmental disorder and other related conditions. Institute. Scientific Proceedings of the American Academy of Child and Adolescent Psychiatry Annual Meeting.1996.

6. Wilens TE, Birmaher B, Coffey B, **Frazier J**, Spencer T, and Wozniak J. Advanced psychopharmacology: Working with complicated cases. Scientific Proceedingsof the American Academy of Child and Adolescent Psychiatry Annual Meeting-Toronto. 1997; page 2.

7. **Frazier JA.** Childhood psychosis. Institute: Optimal Duration of Treatment. Scientific Proceedings of the American Academy of Child and Adolescent Psychiatry. 1999, page 8.

8. **Frazier JA.** Advanced psychopharmacology of psychotic disorders and bipolar disorder in children and adolescents. Scientific Proceedings of the American Academy of Child and Adolescent Psychiatry. 1999; page10.

9. Wozniak J, Biederman J, Mick E, Wilens T, **Frazier JA**. Kowatch R. “Current research findings in pediatric bipolar disorder.” Symposium, Scientific Proceedings, 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA 2002.

10. **Frazier J**. Presentation “The psychopharmacology of aggression” Scientific Proceedings 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry Miami Beach, FL 2003, page 5.

11. **Frazier JA,** Carlson C, Carter A, Pauls D, Guiliano A, Holtzman D, Sikich L. Institute “Childhood major mental illness: New directions from bench to clinic.” Scientific Proceedings 50th Anniversary Meeting of the American Academy of Child & Adolescent Psychiatry Miami Beach, FL 2003, page 10.

12. **Frazier JA,** Presentation “The neurobiology of pediatric bipolar disorder and of schizophrenia.” Scientific Proceedings 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry Miami Beach, FL 2003, page 11.

13. Frazier JA, Giedd J, Nicolson R, Sikich L, Benes F. Symposium “Childhood neuroimaging: Similarities and differences between clinical samples and healthy subjects.” Scientific Proceedings 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry Miami Beach, FL 2003, page 66.

14. Frazier JA. Presentation as part of symposium “Innovative and cross-cultural approaches in child and adolescent psychiatry.” Presentation “Early identification of psychosis in youths.” American Psychiatric Association, 55th Institute on Psychiatric Services. Boston, MA 2003, page 211

15. Frazier JA. Presentation as part of symposium “Neuroimaging Seminar” Presentation “Neuroimaging in Childhood Disorders.” Syllabus and Proceedings Summary of the American Psychiatric Association 2004 Annual Meeting. New York, NY, 2004, page 167.

16. Geller B, Hellander M, DelBello M, Fristad M, Kafantaris V, Scheffer R, Frazier J. “Treatment of Bipolar disorders in Children and Adolescents: New Issues.” Scientific Proceedings 51st Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC 2004, page 52.

17. Wood M, Lapane K, Frazier JA, Nordeng HME. Poster “Prenatal Triptan Exposure is Associated with Externalizing Behaviors in Three Year Old Children” Results From the Norwegian Mother and Child Cohort Study.” 61st Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA 2014, Page 103.

18. Robb AS, McNamara N, Pavuluri MN, Kafantaris V, Scheffer R, Frazier JA, Rynn MA, DelBello MP, Kowatch RA, Rowles B, Lingler J, Martz K, Anand R, Clemons T, Taylor-Zapata P, Findling RL. Poster” Lithium in Acute Treatment of Manic or Mixed Episode in Pediatric Bipolar I Disorder: A Randomized Double–Blind, Placebo –Controlled Study.” 61st Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA 2014, page 149.

19**. Frazier JA**, Wood M, Mick E, Mitchell T, Hodge S, Cochran DM, Kennedy D. Poster ”Magnetic Resonance Imaging of Behavioral Dysregulation in Neurodevelopmental Disorders. 53rd Annual Meeting of American College of Neuropsychopharmacology, Phoenix, Arizona 2014, page 208

***Non-print materials***

1. 2012 Produced Educational Video for Parents, Children and Clinicians on “Clinical Trials in Youth with Mood Disorders”

2. 2012 Produced Educational Video for Parents, Children and Clinicians on “The use of Placebos in Clinical Trials”

**Presentations and Abstracts**

**Invited Presentations*: National & International***

***Keynotes, Plenary Lectures, Grand Rounds (lectures, discussant), Panelist, Moderator, Institute/Symposia speaker***

“Mental Health and Medical Challenges in Autism Spectrum Disorders” *scheduled in 2017*

Plenary Lecturer

5th DOCTRID Conference, University of Limerick, Limerick Ireland

“Psychosis in children and adolescents: biological and environmental risk *scheduled in* 2017

factors including trauma

Lecturer

Traumapsychosis Conference Norway 2017

Kristiansand, Norway

“Multimodal Imaging of Social Cognition in Autism Spectrum Disorders” 2016 Brainn Congress

Sao Paulo, Brazil

“Medical and Psychiatric Comorbidities in Autism Spectrum Disorders and Evidence 2016

Based Interventions”

“Multimodal Imaging and Social Cognition in Autism Spectrum Disorders”

Paul Labourne Symposium on Child Psychiatry 2016

Kansas City, Kansas

“Autism Spectrum Disorders: An Update” 2016 Department of Psychiatry, Grand Rounds

Brown Medical School, Providence Rhode Island

“Evidence Based Interventions for Individuals with ASD” 2015

Forensic Meet and Greet International Call.

National Association of State Program Directors: Division of Forensics

“Research Symposium: Incorporating Neuroscience into Research,” *Speaker,* 2015

Society of Professors Annual Conference

New Orleans, Louisiana

“Autism in a 15 month Bull Terrier and a 10 yo Boy,” *Speaker,* 2015

Zoobiquity Conference

Tufts University School of Medicine and Cummings School of Veterinary Medicine

Boston, MA

“Treating the Child and Adolescent with an Autism Spectrum Disorder,” *Speaker,* 2015Grand Rounds, Einstein Medical Center

Philadelphia, PA

“Autism: Making the Diagnosis and Assessing for Psychiatric and Medical Co-morbid

Conditions” 2014

Parallel Session. The Third China-US Symposium of Pediatrics.

Changsha City, China

“Evidenced Based Interventions for Autism” 2014

Plenary. TheThird China-US Symposium of Pediatrics.

Changsha City, China

“Evidence Based Interventions for Early Onset Psychosis,” *Grand Rounds Speaker* 2014

University of Sao Paulo, Brazil

“Early Onset Psychosis” ***Week-long*** *Seminar Series Speaker, by invitation* 2014

University of Sao Paulo, Brazil.

“Data Blitz,” *Discussant* 2014 The Neuroscience of Youth Depression Conference

The University of North Carolina at Chapel Hill, NC

\*“Treating the Child and Adolescent with an Autism Spectrum Disorder,” *Speaker,* 2014

American Academy Child and Adolescent Psychiatry

(AACAP) January Psychopharmacology Institute. New York, NY

“Climbing Every Mountain: Efforts to Improve Clinical Outcomes and 2012

Quality of Life for Individuals with Autism Spectrum Disorders”

*Plenary Speaker,*

National Association for Dually Diagnosed (NADD) 29th Annual

Conference & Exhibit Show

Denver (Broomfield), CO

“Autism and Early Onset Schizophrenia: What are the Connections” 2012

*Breakfast Consultation*, National Association for Dually Diagnosed

(NADD) 29th Annual Conference & Exhibit Show.

Denver (Broomfield), CO

“Autism”, *Presentation* 2012

National Librarian Boot Camp at Tufts University

Medford, MA

*“*Neuroimaging Breakout Group”, *Co-Leader* 2010

Annual Pediatric Bipolar Disorder Conference.

Cambridge, MA

“Early Onset Psychosis,” *Presentation* 2009

as part of the American Academy of Child and Adolescent Psychiatry-

34th Annual Review Course in Child and Adolescent Psychiatry and Training

Session for the Oral Board

Boston, MA **[organize**r**]**

“Psychopharmacology Workshop, ”*Speaker,* 2008

Evidence-Based Child and Teen Mental Health: The First National

Institute for Primary Care Providers

Arizona State University, Scottsdale, AZ

”Assessing the Presentation, Diagnosis and the Efficacy of Agents Used 2007

in the Treatment of Childhood and Adolescent Schizophrenia,” *Speaker,*

as part of the CME course “Advancing the Treatment of Childhood and Adolescent

Schizophrenia and Bipolar Disorder: The Role of Atypical Antipsychotics.”

Philadelphia, PA

“Assessing the Presentation, Diagnosis and the Efficacy of Agents Used 2007

In the Treatment of Childhood and Adolescent Schizophrenia,” *Speaker,*

at the NIMH Workshop on “Child and Adolescent Onset

Schizophrenia: Research Challenges and Opportunities.”

Bethesda, MD

“Clozapine and Other Atypicals in the Treatment of 2007

Youth with Psychotic Disorders” Seminar, Kansas City, MO

“Clozapine and Other Atypicals in the Treatment 2007

of Youth with Psychotic Disorders” *Speaker,* Pediatric Grand Rounds,

University of Missouri School of Medicine, Kansas City, MO

“First Episode Schizophrenia,” S*peaker,* 2006

XXIV Chilean Congress of the Society of Psychiatry and Neurology of

Infancy & Adolescence. Vina del Mar, Chile

“Antipsychotics,” *Speaker,* 2006

XXIV Chilean Congress of the Society of Psychiatry and Neurology of

Infancy & Adolescence. Vina del Mar, Chile

“Lithium-COLT Study I,” *Speaker ,* 2006

COLT Start Up Meeting, Cleveland, OH

“Prevalence and Presentation of Childhood and Adolescent Mood Disorders,” *Speaker,* 2006

as part of the Conference “Update on Neurobiology and Treatment of Child and Adolescent Psychiatric Disorders” Emory

University, Atlanta, GA

“Psychotic Disorders, Pervasive Developmental Disorders 2006

and Mental Retardation,” *Speaker,*

3rd Psychiatry Congress of the Association of Psychiatrists

in the Bayamon Region. San Juan, Puerto Rico

“White Matter Abnormalities in Children At Risk for and Those with 2005

NIMH Pediatric Bipolar Disorder Conference, Coral Gables, FL

“Childhood Psychosis,” *Grand Rounds Speaker*, 2004

Case Western Reserve University, Cleveland, OH

.

“Pediatric Bipolar Disorder,” *Grand Rounds Speaker ,* 2004

University of Cincinnati, Cincinnati, OH

“Bipolar Disorder and Autistic Spectrum Disorders,” *Speaker,* 2004

CABF Symposium. American Academy of Child and

Adolescent Psychiatry, Washington, D.C.

“Findings from Structural Neuroimaging of Pediatric Patients,” *Presentation* 2002

NIMH Sponsored Research

Workshop: Neurobiology of Bipolar Disorder, Bethesda, MD

“Treatment of Adolescent Psychosis,” *Speaker,* 2002

Annual Psychosis Conference, University of West Virginia, WV

“Methodological Issues and Controversies in Clinical Trials with Child 2002

and Adolescent Patients with Bipolar Disorder.”

*Invited Work Group Member,* American Academy of Child and

Adolescent Sponsored Conference, Chantilly, VA

“Pediatric Bipolar Disorder: Phenomenology, Neurobiology and Treatment,” *Presenter* 2002

7th Annual Neuropsychiatric Pharmacology Update,

Phoenix, AZ

“Pediatric Bipolar Disorder,” *Key Note Speaker*, 2002

National Alliance for the Mentally Ill, North Carolina Annual Conference

Raleigh, NC

“Childhood Psychosis,” *Grand Rounds Speaker,* 2001

University of Vancouver, British Columbia, Canada

“Neuroimaging in ADHD,” *Speaker,* 2001

University of Vancouver, British Columbia, Canada

“Childhood Psychosis and Bipolar Disorder,” *Grand Rounds Speaker,* 2001

Medical College of South Carolina, Charleston, SC

"Neuroimaging and ADHD", *Speaker,* 2001

AD-IN's (Attention Deficit Information Network, Inc.)

Eighth National Conference on ADD,

*Sponsored by* McLean Hospital, Randolph, MA

“Brain Imaging of Children and Adolescents with Psychotic Disorders,” *Presenter,* 2000

American Neuropsychiatric Association, Fort Myers, FL

“Child Psychopharmacology Update,” *Presenter* , 1999

Baylor College, Houston, TX

“Childhood Psychosis,” *Lecture* 1997

National Alliance for the Mentally Ill, Tulsa, OK

“How to Avoid the Risks of Under or Over Medicating.” 1997

National Alliance for the Mentally Ill, Tulsa, OK

**Invited Presentations: *Regional***

“Mental Health and Medical Concerns in Autism Spectrum Disorder” 2016

Speaker, Autism Spectrum Disorder Conference

Harvard Medical School/Cambridge Health Alliance

Cambridge, MA

“Treating the Child and Adolescent with an Autism Spectrum Disorder,” 2014

*Grand Rounds Speaker* Stony Brook, NY

“A Conversation about Depression and Asperger’s Disorder,” *Speaker,* 2014

Annual Asperger’s Association of New England Conference,

Chestnut Hill, MA

“Brain Development,” *Key Note Speech* 2011

Massachusetts Children’s Mental Health Week kick off Conference

Fidelity Bank, Leominster, MA

“Caring for the Patient with Autism,” *Speaker,* 2011

Regional UMMHC/UMMS Conference for the Primary Care Physician

Shrewsbury, MA

“Work Model Internship for Transition Age Youth with Asperger’s Disorder,”

*Grand Rounds Speaker,* 2011

Yale Child Study Center New Haven, CT

“Early Onset Psychosis: What have we learned?” *Speaker,* 2010

Annual Meeting of the Maine Child and Adolescent Psychiatry Association

Sunday River, ME

“Evidenced Based Biomedical Interventions for Autism Spectrum Disorders,” *Speaker,* 2010

Annual Meeting of the Maine Child and Adolescent

Psychiatry Association. Sunday River, ME

“Early Onset Psychosis: What have we learned?” *Psychiatry Grand Rounds Speaker,* 2010

Cornell-Westchester Campus, Westchester, NY

“Early Onset Psychosis: What have we learned?” *Psychiatry Grand Rounds Speaker, 2010*

at Cornell –Downtown Campus, New York, NY

“Early Onset Psychosis: An Update,” *Grand Rounds Speaker,* 2009

Long Island Jewish Medical Center, Long Island, NY

“Early Onset Bipolar Disorder: What Have We Learned?” *Grand Rounds Speaker,* 2007

Maine Medical Center, Portland, ME

“New Developments in Treatment of Pediatric Bipolar Disorder,” *Speaker* , 2006

New England Council of Child and Adolescent Psychiatry Pediatric Bipolar

Disorder Conference. Burlington, MA

“The Pharmacological Management of Psychotic Disorders in Children

and Adolescents,” *Speaker,* 2005

Clinical Pediatric Psychopharmacology: State of the Art Conference.

Albert Einstein College of Medicine, Bronx, NY

“Childhood Psychosis,” *Child Grand Rounds Speaker,* 2005

Zucker Hillside Hospital, Long Island, NY

“Pediatric Bipolar Disorder; What Have We Learned?” *Grand Rounds Speaker, 2005*

Zucker Hillside Hospital, Long Island, NY

“Pediatric Bipolar Disorder,” *Speaker,* 2003

Maine Medical Center, Portland, ME

“Pediatric Psychosis,” *Grand Rounds Speaker ,* 2003

Maine Medical Center, Portland, ME

“Bipolar Disorder in Children and Adolescents,” *Speaker,* 2003

Northeast Nurse Practitioner’s Conference, Westford, MA

“Treatment of Childhood and Adolescent Psychotic Disorders,” *Grand Rounds Speaker,* 2002

Four Winds Hospital, Saratoga Springs, NY

“Childhood Psychosis.” *Lecture* 2001

Cornell Medical Center, New York, NY

“Childhood Psychosis: Differential Diagnosis and Treatment,” *Grand Rounds Speaker,* 2000

Brown University, Providence, RI

“Childhood Psychosis,” *Grand Rounds Speaker,* 1999

New York University, New York, NY

“Childhood Psychosis,” *Grand Rounds Speaker,* 1999

North Shore Children’s Hospital, Long Island, NY

“Childhood Psychosis: Phenomenology and Treatment,” *Presentation* 1999

Eli Lilly Sponsored CME presentation, Bangor, ME

“Childhood Psychosis: Differential Diagnosis and Treatment,” *Grand Rounds Speaker,* 1996

Brown University, Providence, RI

***Invited Presentations – Local***

“ Current Clinical Controversies in Neurodevelopmental Disorders” 2016

Speaker,

New Directions in Neurodevelopmental Disorders Symposium,

Harvard Medical School, Boston, MA

“Depression in Individuals with Autism Spectrum Disorders” 2015

Speaker,

Depression and Bipolar Disorder Support Alliance, McLean Hospital, Belmont, MA

“Multimodal Imaging and Social Cognition in Autism Spectrum Disorders” 2015

Seminar Speaker,

Translational Neuroscience Center Seminar, Children’s Hospital, Boston, MA

“The Assessment and Treatment of Major Depression in Individuals with 2015

Asperger’s Disorder,” *Grand Rounds* *Speaker,*

Harvard University Counseling and Mental Health Services, Cambridge, MA

“Early Onset Psychosis: Pharmacological Intervention,” *Speaker,*  2014

Early Psychosis Workshop

Assumption College, Worcester, MA

***“***Medical and Behavioral Conditions Seen in Individuals with Autism Spectrum Disorders,” 2014

*Pediatric Grand Rounds Speaker,*

Tufts New England Medical Center, Boston, MA

“Our Developing Center for Autism and Neurodevelopmental Disorders,” *Speaker,* 2013

Annual Autism Consortium Conference

Harvard Medical School, Boston, MA

“Just the Facts regarding Child Mental Health,” *Lecturer,* 2013

May Day Mental Health Summit-DMH/Shine Initiative

Clark University, Worcester, MA

“Medical and Behavioral Conditions Seen in Individuals with Autism Spectrum 2013

Disorders,” *Presenter,*

Autism Consortium Annual Meeting, Boston, MA

“Mood Disorders in Children and Adolescents,” *Grand Rounds Speaker,* 2013

UMMS Department of Family Medicine, Worcester, MA

“Mood Disorders in Children and Adolescents,” *Grand Rounds Speaker,* 2013

UMMS Department of Pediatrics, Worcester, MA

“Autism and Schizophrenia: Similarities and Differences,” *Speaker,* 2012

BAER Conference, Massachusetts Mental Health Center, Boston, MA

“GABA and Glutamate in Autism,” *Discussant* 2012

UMMS Psychiatry Department Grand Rounds given by

Dr. David Cochran, Worcester, MA

“Neuroimaging in Autism,” *Discussant* 2011

UMMS Psychiatry Department Grand Rounds given by

Dr. Daniel Fallon, Worcester, MA

“Anxiety and Asperger’s Disorder: Does a Pill a day make the Worries go Away?” 2010

*Speaker,*

Annual Conference for the Asperger’s Association of New England.

MIT, Cambridge, MA

“Early Onset Psychosis: What have we learned?” *Grand Rounds Speaker in Psychiatry,* 2010

McLean Hospital in Belmont, MA

“Evidenced Based Biomedical Interventions for Autism Spectrum Disorders,” *Speaker,* 2010

UMASS Translational Science Retreat. Shrewsbury, MA

“Early Onset Psychosis: An Update,” *Grand Rounds Speaker,* 2009

Department of Psychiatry, UMMS, Worcester, MA

“The Atypical Antipsychotic Controversy: What the Literature Is Telling Us,” 2008

*Grand Rounds Speaker,*

Department of Pediatrics, UMMS, Worcester, MA

“Bipolar Disorder and the Brain: What Neuroimaging Tells Us,” *Speaker,* 2008

“Bipolar Disorder” Conference

Cambridge Hospital / Harvard Medical School, Cambridge, MA

“Early Onset Psychosis: An Update,” *Grand Rounds Speaker,* 2008

Longwood Program.

“Early Onset Psychosis: An Update,” *Grand Rounds Speaker,* 2008

McLean Hospital

“Is it Emotional Reactivity or is it Bipolar Disorder?,” *Speaker*, 2008

Asperger’s Syndrome Connections. Annual Conference of the

Asperger’s Association of New England. Marlborough, MA

“Neuroimaging Studies and Multimodal Treatments of Childhood Schizophrenia,” *Speaker,* 2008

Bipolar Disorder and Schizophrenia in Children and Adolescents:

Diagnostic and Treatment Issues, Letters and Sciences. Boston, MA

“PTEP: A New Boston-Area Clinical Program for Treating Individuals at High 2008

Risk for Developing Psychosis,” *Speaker,* Intervention in Early Psychosis:

From Risk States through the First Episode. Boston, MA

“Pediatric Psychopharmacology,” *Lecturer,* 2008

Annual Meeting of the Massachusetts School Nurses, Sturbridge, MA

“The Multicomplex Child: A Multidisciplinary Approach,” *Lecturer,* 2008

New England Council of Child and Adolescent Psychiatry, Medford, MA

“New Therapeutic Approaches for Autism and Related Disorders,” *Moderator,* 2008

Autism Consortium Annual Retreat*,* Panel Discussion of presenters including:

Mark Bear, PhD, Mriganka Sur, PhD, and Mustafa Sahin, PhD.

MIT, Cambridge, MA

“An Update on Early Onset Psychosis,” *Grand Rounds Speaker,* 2007

Massachusetts General Hospital. Boston, MA

“Treatment of Early Onset Schizophrenia Spectrum Disorders,” *Grand Rounds Speaker*, 2007

Cambridge Health Alliance, Cambridge, MA

“Research Update from the CCAD,” *Pediatric Grand Rounds Speaker,* 2007

Cambridge Health Alliance. Cambridge, MA

“Assessing the Presentation, Diagnosis and the Efficacy of Agents 2007

Used in the Treatment of Childhood and Adolescent Schizophrenia”

*Speaker,* as part of the CME course “Advancing the Treatment of Childhood

and Adolescent Schizophrenia and Bipolar Disorder: The Role of Atypical

Antipsychotics” Boston, MA

“Comorbidity and Psychopharmacology: Differentiating and 2007

Medicating along the Spectrum,” *Speaker,*

Autism Spectrum Disorders: From Childhood through Adulthood Conference.

Cambridge Health Alliance, Harvard Medical School

Cambridge, MA **[organizer]**

“Psychopharmacologic Treatment for Bipolar Disorder: Across the Life Span,” *Speaker*, 2006

Bipolar Disorder” Conference

Cambridge Hospital/Harvard Medical School, Cambridge, MA

“An Overview of the Aggressive Child,” *Speaker,* 2006

The Aggressive Child Insight and Management Conference

Franciscan Children’s Hospital/Boston University School of Medicine, Burlington, MA

“Psychotic Disorders, Pervasive Developmental Disorders and Mental Retardation,” 2006

*Speaker,* Child and Adolescent Psychopharmacology Course, Massachusetts General Hospital,

Harvard Medical School, Boston, MA

“Pediatric Psychosis: An Update,” *Grand Rounds Speaker,* 2006

McLean Hospital, Belmont, MA

“Kids and Meds: First Do No Harm,” *Grand Rounds Speaker*, 2005

Cambridge Health Alliance, Cambridge, MA

“Autistic Spectrum Disorders and Comorbidities,” *Speaker,* 2005

Autism Spectrum Disorders: From Childhood to Adulthood Conference.

Cambridge Health Alliance, Harvard Medical School, Cambridge, MA

“Psychosis in Childhood,” *Speaker*, 2005

Child Neurology Conference Massachusetts General Hospital,

Harvard Medical School, Cambridge, MA

“Pediatric Bipolar Disorder: Brain Images and Treatment,” *Presenter,* 2005

Learning and Brain Conference, Public Information Resources, Inc., Boston, MA

“Neuroimaging in Juvenile Bipolar Disorder,” *Lecturer,* 2005

MGH Psychopharmacology Spring Lecture Series Brain Development and Psychiatry,

Clinical, Genetic, and Neuroimaging Research in Childhood Mental Illness

Massachusetts General Hospital, Boston, MA

“The Newer Atypical Antipsychotics: What the Primary Care Provider Should Know,” 2005

*Presenter,*  Developmental Behavioral Pediatrics Conference,

Boston University, Boston, MA

“Pediatric Bipolar Disorder: What have we learned?” Presenter, 2005

Educational Program, MDDA, Belmont, MA

“Pediatric Psychosis: What Have We Learned?” *Grand Rounds Speaker,* 2005

Cambridge Health Alliance, Cambridge, MA

“Pediatric Psychosis: What Have We Learned?” *Grand Rounds. Speaker*, 2005

Children’s Hospital, Boston, MA

“Pediatric Psychosis: What Have We Learned?” *Grand Rounds. Speaker,* 2005

Longwood Medical Center, Harvard Medical School, Boston, MA

“Pediatric Psychosis: What have we learned?” *Grand Rounds Speaker,* 2004

Franciscan Children’s Hospital, Brighton, MA

“Atypical Antipsychotics in Children,” *Grand Rounds Speaker,* 2004

McLean Hospital, Belmont, MA

“Psychotic Disorders, Pervasive Developmental Disorders and Mental Retardation,” 2004

*Speaker,* Child and Adolescent Psychopharmacology Course,

Massachusetts General Hospital/Harvard Medical School, Boston, MA

“Pediatric Bipolar: Phenomenology, Neurobiology and Treatment,” *Lecturer,* 2004

Child Psychopathology: State of the Art Interventions

Cape Cod Symposium: Eastham, MA

“Pediatric Psychosis/Aggression: Phenomenology, Neurobiology and Treatment,” *Lecturer,* 2004

Child Psychopathology: State of the Art Interventions

Cape Cod Symposium: Eastham, MA

“Developmental Disabilities,” *Lecturer,* 2004

Child Psychopathology: State of the Art Interventions.

Cape Cod Symposium: Eastham, MA

“Atypical Antipsychotic Therapy in Youths,” *Grand Rounds Speaker,* 2003

Franciscan Children’s Hospital, Brighton, MA

“Serious Mental Illness in Young Children: Early Indicators and Interventions,**”** 2003

*Plenary Speaker*, Young Children with Challenging Behavior: What to Know, What to Do.

*Sponsored b*y Lesley University, Framingham, MA

“Strattera: New Medication for ADHD,” *Grand Rounds Speaker,* 2003

McLean Hospital, Belmont, MA

“Childhood Bipolar Disorder,” *Speaker,* 2003

Learning and Brain Conference / MIT, Boston, MA

“Psychotic Disorders in Children: Biology and Treatment,” *Speaker,* 2003

Consolidated Department of Psychiatry,

Harvard Medical School, Boston, MA

“Neuroimaging of disruptive disorders, psychotic disorders and mood disorders,” *Speaker,* 2002

MGH course on Aggressive and Delinquent Youths, Boston, MA

“Child Psychopathology,” *Lecturer,* 2002

Board Review Course, McLean Hospital, Boston, MA

“Mental Retardation (1) Bipolar Disorder (2) and Psychosis (3),” 2002

*Lecturer / full day lecture series* as part of Dr. Barbara Coffey’s Week Long Symposium

Cape Cod Symposium Eastham, MA, *Speaker*

“Psychopharmacology of Aggression,” *Speaker,* 2002

MGH Pediatric Psychopharmacology Course

Boston, MA

“Psychopharmacological Treatment of Pervasive Developmental Disorders and 2002

Psychotic Disorders in Children and Adolescents,” *Speaker,*

MGH Pediatric Psychopharmacology Course

Boston, MA

“Neuroimaging in Pediatric Bipolar Disorder,” *Speaker,* 2002

Bipolar Disorder in Children Conference, Boston, MA

“Emotional and Behavioral Difficulties in the Developmentally 2001

Disabled: Pharmacological Interventions,” *Keynote Speaker,*

17th Annual Conference: Franciscan Children’s Hospital. Needham, MA

“Pediatric Bipolar: Phenomenology, Neurobiology and Treatment,” *Presentation* 2001

Pediatric Psychopharmacology: Cape Cod Symposium, Eastham, MA

“Pediatric Psychosis: Phenomenology, Neurobiology and Treatment,” *Presentation* 2001

Pediatric Psychopharmacology: Cape Cod Symposium, Eastham, MA

“Developmental Disabilities,” *Lecturer,* 2001

Pediatric Psychopharmacology: Cape Cod Symposium, Eastham, MA

“Phenomenology and Treatment of Children with Schizophrenia,” *Presenter,* 2001

1st Annual Course in Major Psychiatric Illness in Children and Adolescents,

Consolidated Department of Psychiatry, Harvard Medical School

Fairmont Hotel, Boston, MA

“Bipolar Disorder,” *Speaker,* 2001

Awesome Adolescents Conference

McLean Hospital, Charles Hotel, Cambridge, MA

“Pediatric Bipolar Disorder,” *Speaker,* 2001

Western Massachusetts Psychiatric Society, Holyoke, MA

“Pervasive Developmental Disorder and Attention Deficit Hyperactivity Disorder,” *Speaker,* 2001

Child and Adolescent Psychopharmacology,

Massachusetts General Hospital, Boston, MA

“Pediatric Schizophrenia and Bipolar Disorder,” *Grand Rounds Speaker,* 2000

McLean Hospital, Belmont, MA

“Psychotic Disorders, Pervasive Developmental Disorders, and Mental Retardation,” 2000

*Speaker,* Child and Adolescent Psychopharmacology,

Massachusetts General Hospital/Harvard Medical School, Boston, MA

“Psychopharmacology of Aggression,” *Speaker* , 2000

Child and Adolescent Psychopharmacology,

Massachusetts General Hospital/Harvard Medical School, Boston, MA

“Psychopharmacology Update: “Treatment of Childhood Psychosis and Bipolar Disorder,” 1999

*Speaker,* Massachusetts Psychiatric Society, Dedham, MA

“Violence in Children, Adolescents and Families: Strategies for Prevention 1999

and Clinical Intervention,” *Presenter,* Workshop: Psychopharmacology of

Aggression: Clinical Cases Consolidated Department of Psychiatry,

Harvard Medical School

“Neuroimaging in Patients with Attention Deficit/ Hyperactivity Disorder,” *Speaker,* 1999

American Psychological Association Annual Meeting, Boston, MA

“Kids and Violence,” *Grand Rounds Speaker,* 1999

McLean Hospital, Belmont, MA

“Childhood Psychosis,” *Grand Rounds Speaker,* 1998

Pembroke Hospital, Pembroke, MA

“Childhood Psychosis,” *Psychopharmacology Grand Rounds Speaker,* 1998

McLean Hospital, Belmont, MA

“Psychosis and Pervasive Developmental Disorders in Children and Adolescents,” *Speaker,* 1998

Child and Adolescent Psychopharmacology Conference

Massachusetts General Hospital, Westin Hotel, Boston, MA

“Psychopharmacology: Efficacy and Utilization in Treatment of Children and 1998

Adolescents,” *Speaker,* Massachusetts Behavioral Health Partnership,

Bentley College, MA

“Juvenile Bipolar Disorder and Childhood Psychosis," *Speaker*, 1997

Massachusetts Psychiatric Society-Psychopharmacology Conference, Dedham, MA

"Psychopharmacological management in infants and toddlers,” *Speaker,* 1997

Annual Boston Institute for the Development of Infants and Parent’s Conference

Medford, MA

“How to Avoid the Risks of Over and Under Medication,” *Speaker,* 1997

New Pharmacology in Children and Adolescents Department of Mental Health

Annual Conference on Child Services, Westborough, MA

Attention Deficit Hyperactivity Disorder Across the Life Span “Comorbidity of 1997

ADHD with Developmental Disorders,” *Speaker,* MGH Conference, Westin Hotel,

Boston, MA

“State of the Art Psychopharmacology: “Pharmacological Treatment of Childhood 1997

Psychosis,” *Speaker,* McLean Hospital, Belmont, MA

“Bipolar Disorder: Diagnosis and Treatment of Bipolar Disorder with Comorbid 1997

Disorders in Children and Adolescents,” *Grand Rounds Speaker*, McLean Hospital,

Belmont, MA

“Childhood Onset Schizophrenia: Phenomenology, Neurobiology, and Treatment,” 1996

*Grand Rounds Speaker,* Massachusetts General Hospital, Boston, MA

“Child and Adolescent Psychopharmacology Course “Curbside Consultation,” 1996

*Consultant,* MGH/Harvard Medical School, Boston, MA

**National/International Meetings (Peer-reviewed Presentations)**

**Symposia Contributions (Chair, Co-Chair, Discussant, Presenter), Institutes**

**(Leader, Speaker, Panelist), Presentations (Speaker, Poster)**

“Trajectories and Treatment Neuroscience in Pediatric Mania.” 2016

*Discussant* for Symposium

63rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

New York, New York

“Trajectories of Irritability in Childhood Predict Adult Diagnostic Outcomes.” *Contributor* as 2016

part of symposium “Disruptive Mood Dysregulation Disorder and Other Psychopathology: Present and Future.”

63rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

New York, New York

“Therapeutic Possibilities of Neurofeedback: New Developments and Findings.” 2016

*Discussant* for Symposium

63rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

New York, New York

“Assessing Impact of Mental Health Education for Adolescents in Rural Costa Rica.” 2016

*Author* on Poster

63rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

New York, New York

“Anatomic Relationships Between Emotional and Behavioral Dysregulation and Irritability 2015

in Neurodevelopmental Disorders**”** Presenter and **Chair for Symposium** “Neuroscience

of Irritability.”

62nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

San Antonio, Texas

“Lithium Biodisposition and Dosing in Youth with Bipolar I” Presenter as part of symposium 2015

“Finding From the Collaborative Lithium Trials.”

62nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

San Antonio, Texas

“Potential Biomarkers of Social Cognition in Autism and Schizophrenia” **Symposium Chair** 2015

62nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

San Antonio, Texas

“Magnetic Resonance Imaging of Behavioral Dysregulation in Neurodevelopmental 2014

Disorders,” *Poster Presentation*

53rd Annual Meeting of American College of Neuropsychopharmacology,

Phoenix, Arizona

“Prenatal Triptan Exposure is Associated with Externalizing Behaviors in Three 2014

Year Old Children” Results From the Norwegian Mother and Child Cohort Study,”

*Poster Presentation* 61st Anniversary Meeting of the American Academy of Child

and Adolescent Psychiatry, San Diego, CA

“Lithium in Acute Treatment of Manic or Mixed Episode in Pediatric Bipolar I Disorder: 2014

A Randomized Double–Blind, Placebo –Controlled Study,” *Poster Presentation*

61st Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry,

San Diego, CA

“Data Blitz Featuring Early Career Investigators,” *Discussant* 2014

61st Annual Meeting of the American Academy of Child and Adolescent Psychiatry

San Diego, CA

“Complementary and Integrative Medicine: Neurofeedback, LORETA, Quantitative EEG,

and Personalized Medicine, ” *Discussant Clinical Perspectives*

61st Annual Meeting of the American Academy of Child and Adolescent Psychiatry

San Diego, CA

“Emerging Young Adults with Autism Spectrum Disorders: Bridging the Divide in 2013

Available Services” Presenter and ***Chair*** *for Symposium “Treatment of*

*Emerging Young Adults with Psychiatric* *Needs”* Annual Meeting of American

Academy of Child and Adolescent Psychiatry (AACAP)

Orlando, Florida

“Evidence Based Treatments for Psychosis in Youth,” *Presenter and* ***Institute Co-Chair*** 2013

*with Dr. Dvir*, for *“Psychotic Disorders in* *Youth: Diagnostic and Treatment*

*Considerations”* Annual Meeting of American Academy of Child and Adolescent

Psychiatry (AACAP)

Orlando, Florida

“Brain Developmental Trajectories in Childhood Onset Neuropsychiatric Disorders,” 2013

(*Symposium Discussant)* Annual Meeting of American Academy of Child and

Adolescent Psychiatry (AACAP)

Orlando, Florida

“Psychosis in Children and Adolescents: What the Literature is Telling Us” 2013

*Presentation for Symposium*: *“Improving the Quality of Care for Patients*

*with Early Onset Psychosis”* Annual Meeting of American Academy

of Child and Adolescent Psychiatry (AACAP)

Orlando, Florida

“Clinical Application of DSM-5: Psychosis/Attenuated Psychosis” 2013

*Presentation for Symposium: “Symposium “DSM-5”*

Annual Meeting of AACAP, Orlando, Florida

“Data Blitz,” *Discussant* 2013

Annual Meeting of AACAP, Orlando, Florida

“Can Brain Findings Inform Clinical Work in Child Psychiatry?” *Symposium Discussant* 2012

59th Annual Meeting of the American Academy of Child and Adolescent Psychiatry

San Francisco, CA

“Glutamate and GABA Function in Autism Spectrum Disorders: 2012

A Proton Magnetic Resonance Spectroscopic Study,” *Poster Presentation,*

59th Annual Meeting of the American Academy of Child and Adolescent Psychiatry

San Francisco, CA

“Neuroimaging Correlates and Their Association with Emotion Recognition Accuracy 2012

and Social Functioning in Adolescents with Autism,” *Poster Presentation*

59th Annual Meeting of the American Academy of Child and Adolescent Psychiatry

San Francisco, CA

“Neuroimaging in Clinical Practice: Are We There Yet?” *Symposium Discussant* 2012

59th Annual Meeting of the American Academy of Child and Adolescent Psychiatry

San Francisco, CA

“Mood and Trauma. What are the Associations?” *Poster Presentation* 2011

Joint Meeting: American and Canadian Academies of Child and Adolescent Psychiatry

A AACAP+CACAP, (58th Annual Meeting of AACAP), Toronto, Canada

“Early Onset Psychosis” *Presentation* as part of the American Academy of Child and 2009

Adolescent Psychiatry - 34th Annual Review Course in Child and Adolescent Psychiatry

and Training Session for the Oral Board

Boston, MA **[major organizer]**

“Recognition, Diagnosis, and Treatment of Childhood - Onset Bipolar Disorder,” 2008

*Presentation for Symposium: “Treatment of Children and Adolescents with*

*Psychiatric Disorders: The Rising Use of Antipsychotics”*

Annual Meeting, American Psychiatric Association, Washington, DC

“Neuroimaging” *Presentation for Workshop*: 2008

*“The future of Psychiatry: Utilizing a neurodevelopmental model for case formulation.”*

Annual Meeting of the American Psychiatric Association, Washington, DC

“Phenomenologic Aspects of Disease in Bipolar Disorder” 2008

*Presentation for Symposium: entitled “Progressive Effects of* *Bipolar*

*Disorder Across the Life Span”* Annual Meeting, Society of Biological Psychiatry,

Washington, DC

“Neuroimaging and Treatment of Pediatric Bipolar Disorder” 2008

*Presentation for Symposium: Mapping the Development of Cortical Circuits Through*

*Adolescence in Healthy Subjects and Neurodevelopmental Disorders”*

Annual Meeting, Society of Biological Psychiatry, Washington, DC

“Comparison of Molindone, Olanzapine and Risperidone for Acute Antipsychotic 2007

Treatment,” *Panel Presentation*, for panel entitled “*Treatment of Early-*

*Onset Schizophrenia Spectrum Disorders*” Annual Meeting of the American College of Neuropsychopharmacology

Boca Raton, FL **[co-chair]**

“Early Onset Psychosis: Pubertal and Sex Effects on Subcortical Gray Matter Volumes” 2007

*Panel Presentation*, for panel entitled “*Puberty, Sex, Brain and Behavior*”

Annual Meeting of the American College of Neuropsychopharmacology,

Boca Raton, FL **[co-chair]**

“Early-Onset Bipolar Disorder: Pubertal/Sex Effects on the Limbic Network , 2007

*Symposium Presentation* for symposium entitled*: “Treatment of Early-Onset*

*Schizophrenia Spectrum Disorders”* Annual Meeting, American Academy of

Child and Adolescent Psychiatry, Boston, MA

“Comparison of Molindone, Olanzapine and Risperidone for Acute Antipsychotic 2007

Treatment,” *Symposium Presentation* for symposium entitled “*Treatment of Early-*

*Onset Schizophrenia Spectrum Disorders*.” Annual Meeting of the American Academy

of Child and Adolescent Psychiatry, Boston, MA

“Treatment of Early Onset Schizophrenia Spectrum Disorders Study (TEOSS): 2007

Metabolic Side Effects and Safety Profile” *Panel Presentation* for panel entitled

“*Atypical Antipsychotic Medications: Effectiveness and Safety across the Life Cycle”*

New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL

“Protective and Risk Factors in Pediatric Bipolar Disorder: Predicting Outcomes” Research 2006

Forum: *Rapporteur, Neuroimaging Break Out Group*  Annual Meeting, American

Academy of Child and Adolescent Psychiatry, San Diego, CA

“Neurocognition in Early Onset Schizophrenia: Relationship to, Diagnosis Symptoms 2006

and Communication”*Symposium Presentation* for Symposium entitled “*Initial*

*Findings from the Early Onset Schizophrenia Spectrum Disorder Research Group*”

Annual Meeting, American Academy of Child and Adolescent Psychiatry, San Diego, CA

“Early Onset Schizophrenia: A Research Update,” *Discussant 2*006

Annual Meeting, American Academy of Child and Adolescent Psychiatry,

San Diego, CA

“Neuroimaging in Childhood Disorders,” *Symposium Presentation* 2004

for Symposium entitled *Neuroimaging Seminar* American Psychiatric Association

Annual Meeting, New York, NY

“Early Identification of Psychosis in Youths.” *Symposium Presentation* for Symposium 2003

entitled *“Innovative and Cross-Cultural Approaches* *in Child and Adolescent Psychiatry”*

American Psychiatric Association, 55th Institute on Psychiatric Services, Boston, MA

“Childhood Bipolar Disorder and Schizophrenia: Phenomenology, Neurobiology and 2003

Treatment,” *Speaker,* American Psychiatric Association, 55th Institute on Psychiatric

Services, Boston, MA

“Early identification of psychosis in youths.” *Institute Presentation* for “*Innovative and* 2003

*cross-cultural approaches in child and adolescent* *psychiatry*.” American Psychiatric

Association, 55th Institute on Psychiatric Services, Boston, MA

“The Psychopharmacology of Aggression,” *Institute Speaker* 2003

American Academy of Child and Adolescent Psychiatry Annual Meeting,

Miami Beach, FL

“Childhood major mental illness: New directions from bench to clinic,” *Institute Speaker* 2003

American Academy of Child and Adolescent Psychiatry Annual Meeting,

Miami Beach, FL

“The neurobiology of pediatric bipolar disorder and of schizophrenia,” *Institute Speaker* 2003

American Academy of Child and Adolescent Psychiatry Annual Meeting,

Miami Beach, FL

“Childhood neuroimaging: Similarities and differences between clinical samples 2003

and healthy subjects.” *Symposium Presenter,*

American Academy of Child and Adolescent Psychiatry Annual Meeting,

Miami Beach, FL

“Psychotic Illness in Children- Treating Psychotic Illness Across the Lifespan: 2002

Are Drugs Enough?” *Symposium Presentation,* American Psychiatric Association

Annual Meeting, Philadelphia, PA

“Neuroimaging of Pediatric Bipolar Disorder,” *Symposium Speaker* for “*New Research 2002*

*Findings in Pediatric Bipolar Disorder*” American Child and Adolescent Academy

Meeting, San Francisco, CA

“Anatomic Brain Magnetic Resonance Imaging (MRI) in Pediatric Bipolar Disorder,” 2001

*Symposium Speaker,* American Academy of Child and Adolescent Psychiatry

Annual Meeting, Honolulu, HI

“ADHD Across the Life Span: “Neuroimaging in Patients with ADHD,” *Presenter* 2000

American Psychiatric Association Annual Meeting, Chicago, IL

“Childhood-Onset Schizophrenia?” *Speaker,* 2000

American Academy of Child and Adolescent Psychiatry Annual Meeting

Toronto, Canada

“Childhood Psychosis and Bipolar Disorder” *Institute Speaker* for Institute: 1999

*Advanced Psychopharmacology: Contemporary Issues* *in Clinical Care*

American Academy of Child and Adolescent Psychiatry Annual Meeting, Chicago, IL

“Childhood Psychosis” *Institute Speaker* for Institute: 1999

*Establishing Optimal Duration of Treatment*

American Academy of Child and Adolescent Psychiatry Annual Meeting, Chicago, IL

“From Neurobiology to Psychopharmacology: Recent Research in Adult with 1999

Attention Deficit Disorder,” *Symposium Presentation,* American Academy of Child

and Adolescent Psychiatry Annual Meeting, Chicago, IL

“Childhood Onset Schizophrenia, Pervasive Developmental Disorder and Other 1996

Related Conditions,” *Institute Speaker,* American Academy of Child and

Adolescent Psychiatry, Philadelphia, PA

“Mania and Pervasive Developmental Disorder,” *Symposium Speaker,* 1996

American Academy of Child and Adolescent Psychiatry, Philadelphia, PA

“FMRI of Adults with Childhood Onset Attention Deficit Hyperactivity Disorder,” 1996

*Research Presentation,* American Academy of Child and Adolescent Psychiatry,

Philadelphia, PA

“Childhood Onset Schizophrenia,” *Symposium Presentation* 1995

American Academy of Child and Adolescent Psychiatry, New Orleans, LA

“Special Topics in Psychopharmacology: Pharmacological Treatment of Childhood 1995

Schizophrenia,” *Institute Speaker,* American Academy of Child and Adolescent

Psychiatry, New Orleans, LA

“Striatal Pathology in Schizophrenia: Developmental, Disease or Treatment Effect?” 1994

*Study Group,* American College of Neuropsychopharmacology, San Juan, Puerto Rico

“Why Study Teenagers with Psychosis?” *Study group,* 1994

American College of Neuropsychopharmacology, San Juan, Puerto Rico

“DSM-IV versus Child Manual? Childhood Schizophrenia,” *Symposium Speaker,* 1994

American Academy of Child and Adolescent Psychiatry, New York, NY

**Committee Assignments and Administrative Service**

**International Service- Advisory Panels**

*Scientific Advisory Committee* 2016-2018

International Early Psychosis Association Meeting

**National Service*-Grant Review***

*NIH Study Section Service*

Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section

(NPAS), 2009-2015

Center for Scientific Review (Member),

National Institutes of Health [(**standing member) Chair, 2014-2015**]

National Institute of Mental Health BSC (Ad Hoc Reviewer) June 2009

National Institutes of Health Review Committee, NPAS (Ad Hoc Reviewer) June 2009

National Institute of Mental Health Review Committee ZMH 1 ERB-B 03 R- 2007

March 20, 2007

*Other Grant Reviews*

Department of Defense Autism IDEA Award (Grant Reviewer) 2015

Autism Treatment Network (Grant Reviewer) 2009

**National Service- *Advisory Panels, Workgroups***

Child and Adolescent Task Group, National Network of Depression Centers (Co-Chair) 2012 - pres.

CTSA Consortium, Child Health Oversight Committee, NIH-CC-CHOC 2012

National Institute of Mental Health: Domain Criteria Project: Positive Valence Systems 2011

Workshop, Bethesda, MD

Professional Advisory Council for the Child and Adolescent Bipolar 2003 - pres.

Foundation Renamed as “The Balanced Mind Parent Network”

**National Service - *American Academy of Child and Adolescent Psychiatry***

Research Committee, Society of Professors, American Academy of 2014 - pres

Child & Adolescent.Psychiatry (Co-Chair)

Research Committee, American Academy of Child and Adolescent Psychiatry 2012 - pres.

(Co-Chair 2015- pres.)

Program Committee, American Academy of Child and Adolescent Psychiatry 2010 - 2015

(Coordinator Clinical Case Conferences)

Selection Committee for the EOP and CAP travel awards given by 2007 - 2008 American Academy of Child and Adolescent Psychiatry

Committee on Integrated Research Training Programs in Child Psychiatry, 2006 - 2007

American Academy of Child and Adolescent Psychiatry

Work Group on Research, American Academy of Child and Adolescent Psychiatry 2005 - 2008

***National Service – Committee service, external institutions***

Morley Medal Scientific Award Selection Committee 2014 - pres

Western Reserve Academy, Hudson, Ohio

U54 “Rescuing Fragile X Syndrome by Resetting Translational Homeostasis,” 2014 - pres.

Three Site Study Executive Committee

Credentials Committee, American College of Neuropsychopharmacology 2010 - 2012

History Committee, American College of Neuropsychopharmacology 2007 - 2009

***National Service - Data Safety Monitoring Boards***

Data Safety Monitoring Board for Forest Pharmaceuticals for VLZ-­‐MD  study 2013 - 2016

Data Safety Monitoring Board for TSC Study, [Randomized, Double Blind Phase II 2011 - 2015

Trial of RAD001 for Neurocognition in Individuals with Tuberous Sclerosis Complex

At Children’s Hospital in Boston: PI: Dr. Sahin

Data Safety Monitoring Board for All Clinical Trials in Child and Adolescent and Adult 2006 - 2014

Psychiatry at Zucker Hillside Hospital, New York

Data Safety Monitoring Board for Stanley Early Onset Bipolar Disorder Treatment 2005 - 2010

Study at University of Cincinnati: PI: Robert Kowatch

**Regional Service**

***Regional Service - Committees, Advisory Boards, Workgroups***

Advocates for Autism of Massachusetts, Advisory Council 2016-pres.

Program Committee, Annual Meeting of the Asperger’s Association of New England 2011

Advisory Board for the New England Center for Autism 2010 - pres.

Steering Committee of the Autism Consortium in Boston 2006 - 2015

Scientific Advisory Board for Step-Up for Kids 2005 - pres.

Board of New England Council, Child and Adolescent Psychiatry 2000 – 2003

***Service to the Commonwealth of Massachusetts***

Psychopharmacology Work Group, Department of Mental Health 2016 – pres.

Autism Spectrum Disorder Task Force, Department of Mental Health 2014 - pres.

Association of University Centers on Disabilities (AUCD), “Act Early”, Region 1 2010 - pres.

summit on autism spectrum disorders, co-sponsored by the Centers for Disease

Control and Prevention (CDC) (member of Massachusetts state team)

Mental Health Parity Advisory Group, Department of Mental Health 2009

Psychopharmacology Experts Workgroup, Department of Mental Health, 2006 - 2010

Massachusetts

Clinical Advisory Committee, Massachusetts Behavioral Health Partnership 2001 - 2002

Research Review Committee, Massachusetts Department of Mental Health 1989 - 1991

**Local Service to Home Institution**

***University of Massachusetts Medical School, Worcester, MA: School Service***

6th Annual UMCCTS Research Retreat Committee 2016

Clinical Trial Management Steering Committee 2016 - pres.

Diversity Planning Committee 2012 - 2015

Violence Work Group - Worcester Recovery Center and Hospital 2012 - 2013

Search Committee for the Chair of Pediatrics and the Chief of the Children’s 2011 - 2012

Medical Center

“Light it up Blue for Autism – Organizing Committee 2010 - pres.

Chancellor’s Scholar Award Committee 2010 - 2015

Human Excellence 2012: HR Content Committee 2010 - 2011

Women’s Faculty Leadership Work Group 2009 - pres.

National Children’s Study-UMASS Advisory Board 2008 - 2013

***UMass Memorial Health Care System, Worcester, MA: Hospital Service***

UMMS Diversity Committee 2012 - 2015

Behavioral Health Committee, UMMHC 2011 - pres.

Psychiatry Service Line Committee, UMMHC 2011 - 2014

Children’s Medical Center Restructuring Committee 2009 - 2010

***University of Massachusetts Medical School, Worcester, MA: CHPR/CWM***

CWM Strategic Planning meeting 2016 - pres

Shriver Strategic Planning Group 2016 - pres

CHPR Senior Leadership Group 2016 - pres

Supporting Children and Transition Age Youth with Disabilities Group 2016 - pres

***University of Massachusetts Medical School, Worcester, MA: Psychiatry Department***

Neurodevelopmental Disorders Research Interest Group 2015 - pres

Clinical Research Workgroup 2009 - pres.

Ethics Committee, Psychiatry Department 2009 - pres.

Neuroimaging Academic Interest Group 2009 - pres.

Reproductive Psychiatry Academic Interest Group 2009 - 2012

Autism Academic Interest Group 2008 - 2014

Psychiatry Leadership Group 2008 - pres.

Executive Committee, Department of Psychiatry 2008 - pres.

Implementation Committee, Department of Psychiatry 2008 - 2009

Executive Committee, Division of Child and Adolescent Psychiatry *(Chair)* 2015 - pres.

Steering Committee, Division of Child and Adolescent Psychiatry *(Chair)* 2008 - pres.

Adult and Child Psychiatry Residency Selection Committee 2008 - pres.

Adolescent Transitions Unit, Advisory Board, Worcester State Hospital *(Chair)* 2008 - 2014

*Harvard Medical School, Boston, MA*

Research Committee, sponsored by the HMS Executive Committee in Psychiatry 2005 - 2008

HMS Clinical Research and Educational Council 2004 - 2008

*Cambridge Health Alliance, Cambridge, MA*

Attention Deficit Hyperactivity Disorder, Task Force 2008

Child Psychiatry Leadership Committee 2006 - 2008

Teaching and Education Committee, Child Psychiatry Division 2004 - 2008

*Massachusetts General Hospital/McLean Hospital*

Training Committee, Child and Adolescent Psychiatry Fellowship 2001 - 2004

*McLean Hospital*

Teaching and Education Committee 2000 - 2004

Continuing Education Committee 1999 - 2003

*National Institute of Health*

NIMH Representative to the NIH Committee of Staff Fellows 1993 - 1995

*Emma Pendleton Bradley Hospital-Brown Medical School*

Medical Records Committee 1992 - 1993

*New England Medical Center – Tufts Medical School*

Psychiatry Residents’ Council (Founder and President) 1989 - 1991

Training and Education Committee (PGYII Representative) 1988 - 1989

*Dartmouth Medical School, Hanover, NH*

Grading Policy Review Committee 1985 - 1986

Student Government (Class Representative) 1983 - 1985

Community Service

Numerous community based educational activities through Tea with MDs, 2010 - pres.

and Be Mentally Well